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ABSTRACT 
 Dolabriferol is a polypropionate natural product first isolated by Gavagnin and 
coworkers from the skin of the anaspidean mollusk, Dolabrifera dolabrifera. An unusual 
structural feature of dolabriferol is its noncontiguous carbon backbone that is proposed to arise 
via a retro-Claisen rearrangement of the cyclic hemiacetal precursor 164, perhaps as an artifact 
of isolation. Computational evaluations of the various cyclization/rearrangement manifolds 
available to the acyclic precursor 4 have suggested that the pathway to dolabriferol from linear 
precursor 4 is plausible.  
 
 The research presented herein describes the total synthesis of putative precursor 4, 
evaluation of its properties, and a study of its retro-Claisen rearrangement. This study 
 v 
 
ultimately gave dolabriferol which suggests this compound may be formed during isolation; 
thus, the linear precursor 4 (along with its tautomeric forms) is a plausible natural product. This 
is the first total synthesis of dolabriferol via its putative precursor 4. Previous synthetic 
attempts/syntheses either involve esterification or induce retro-Claisen mid-stage to give 
dolabriferol. The approach to the synthesis of 4 involves aldol coupling of the readily available 
tetrapropionate fragment (±)-141 with enantioenriched aldehyde 124 furnishing 142, a reaction 
that proceeded with kinetic resolution. The enantioenrichment of 124 is derived from a proline-
catalyzed intermolecular aldol reaction of 75 with isobutyraldehyde furnishing 97 (dr >20:1, er 
24:1). Subsequent functional group manipulations of 142 provided the desired 4 as a mixture of 
hemiacetals.  
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INTRODUCTION 
1.1.  Introduction to Structures, Biosynthesis, and Studies of Dolabriferol 
1.1.1. Opisthobranchs and the Curious Chemist 
 Opisthobranchs are gastropod mollusks found exclusively in marine habitats around the 
globe. A common attribute among these mollusks is the lack of a complete shell, with only a 
few species having shells big enough for the animal to completely withdraw itself. For most 
cases, the shell is either reduced in size, internalized, or lost completely. Very often, non-
shelled gastropods are characterized as being slimy and unattractive with the connotation 
usually referring to their terrestrial counterparts. The Opisthobranchs are much different 
showing a vast color array between species but their grand color schemes and beauty are only 
witnessed by deep sea divers.1 
 Only a few thousand species comprise the Opisthobranchs with most animals never 
exceeding ten centimeters in length. Externally, the Opisthobranchs show little evolutionary 
difference between other mollusks. Their chemical biology, however, is very unique within the 
animal kingdom often relating to foraging or defensive strategies. These include usage of intact 
chloroplasts from algal cells for feeding strategies, storage of intact cnidocysts (organelles 
capable of penetrating target organisms and injecting toxins) from cnidarians, the ability to 
synthesize toxic compounds, or to uptake secondary metabolites to chemically arm themselves 
against potential predators. From a biochemical standpoint, isolation and synthesis of these 
metabolites and toxic compounds are important for understanding their role in the chemical 
ecology.1 
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 Despite their size and primitive stature in the animal kingdom, these mollusks are 
capable of producing an array of metabolites with diverse structural and dense stereochemical 
manifolds. Among the metabolites isolated, a large number are polypropionate based with 
some showing pharmaceutical activity; for example, some compounds are able to cure 
infections in patients who are sensitive to penicillin. The ongoing interest in natural products on 
their origin, their pharmaceutical activity, and sheer curiosity in their possible synthesis has 
pushed the field into developing methodology to allow access to these complex and interesting 
molecules. Although there has been extensive development in polypropionate synthesis, many 
natural products still pose a challenge to mimic in a laboratory setting. 
1.1.2. From Simple Chains to Architecturally Complex Molecules 
 Before discussing polypropionate based natural products and their importance, the 
biosynthesis of such compounds is noteworthy. Polypropionates are formed by an extension of 
the polyketide process shown in Scheme 1.1. In organisms, the polyketide process begins with 
formation of an acyl anion equivalent of malonyl CoA through anionic decarboxylation. Addition 
of this intermediate to acetyl CoA forms acetoacetyl CoA and, if the process is allowed to 
continue, formation of longer chains is possible. From here, a wide variety of natural product 
classes can emerge, from aromatic compounds and lactones to unsaturated fatty acids and 
polyacetates.2 
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Scheme 1.1: Simplified Overview of Polyketide Biosynthesis  
 Scheme 1 illustrates select transformations that enzymes are capable of performing as 
part of the polyketide pathway. The steps shown are not necessarily the order of functional 
group manipulations and may in fact exist in any possible order. Therefore, the complete 
carbon skeleton does not have to be synthesized directly, in fact, methylations, reductions, 
eliminations, hydrogenations, cyclizations, and many other changes can occur before the 
complete carbon skeleton is assembled. Looking specifically at methylations, reductions, and 
carbon extensions as the sole reactions allowed provides access to linear compounds with 
dense stereochemical arrays. Every methylation or reduction that occurs, results in two more 
stereoisomers being possible. By methylating once at every position adjacent to a carbonyl or 
hydroxy functionality, moves the class of natural products from polyketides into the realm of 
polypropionates. Methylation of polyketides is not the predominant biosynthetic pathway to 
polypropionates; in fact, a similar route starting with methyl malonyl CoA exists and gives rise 
to the many known polypropionate natural products. The pathway begins by forming the acyl 
anion equivalent of methylmalonyl CoA by anionic decarboxylation and addition to propionyl 
CoA forming intermediate 2. Subsequent carbon extension with methylmalonyl CoA and 
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reductions with ketoreductases provide natural products with alternating methyl and 
hydroxy/ketone substitution down the carbon backbone.    
 
Scheme 1.2: Possible Biosynthesis of Polypropionates 
 Not only are enzymes extremely efficient at synthesizing the long carbon chains, they 
are able to selectively produce a single stereoisomer with amazing turnover making them true 
masters of organic synthesis. The linear polyketides that are formed are not always the final 
product. In many cases, the linear form can undergo various reactions to form compounds that 
are no longer linear (Figure 1.1).  
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Figure 1.1: Complex Natural Products from a Common Precursor  
 In the above example (Figure 1.1), a single linear precursor 3 can undergo various 
reaction pathways to form three unique natural products; all found in extracts of the sea 
mollusk Siphonaria zelandica. It was unclear if the three natural products were formed 
enzymatically or if precursor 3 was the biosynthetic product and baconipyrone A, baconipyrone 
C, and siphonarin B were artifacts of isolation. Despite their efficiency in assembling these 
unique molecules, the amount of material that can be harvested for testing and analysis is very 
limited, requiring synthetic material to test the origin of these natural products. In 2010, the 
linear precursor 3 was prepared by total synthesis and under mild conditions, was converted to 
each of the isolated natural products. These natural products were prepared from 3 without 
the use of enzymes to induce rearrangements, which suggests that these compounds may in 
fact be artifacts of isolation.3 
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1.2. Dolabriferol  
1.2.1. Isolation, Structure Determination, and Biosynthesis 
 Dolabriferol was first isolated by Gavagnin and co-workers from the skin of the 
anaspidean mollusk, Dolabrifera dolabrifera.4 The specimens were collected off the coast of 
Cuba by SCUBA divers and the animals were frozen and immediately transferred. The frozen 
animals were soaked in acetone and the extract purified to afford pure dolabriferol (7.5 mg). 
The relative configuration of 1 was determined by X-ray crystallography but the absolute 
configuration was unknown until the first total synthesis of 1 by Vogel et al.5 
 
Scheme 1.3: Formation of Dolabriferol via Retro-Claisen Rearrangement 
 In 1996, Gavagnin commented on the unique structure of dolabriferol by saying "it is 
very surprising the finding of an ester obtained by coupling a polypropionate acid with a 
polypropionate alcohol." However, he proposed a tentative rationalization that 1 could be 
derived from the linear polypropionate precursor 4 by ring closing of the C-11 hydroxy onto the 
C-7 carbonyl. The cyclic hemiacetal 5 could then undergo retro-Claisen rearrangement forming 
the ester linkage and furnishing dolabriferol 1 (Scheme 1.3). Although the pathway shows 
precursor 4 going directly to dolabriferol, in reality, an enormous number of competing 
reactions are possible. If the linear precursor is allowed to cyclize, undergo retro-Claisen 
rearrangment, eliminate, and so on; one could envision a myriad of products.  
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1.2.2. Computational Studies by Goodman 
 In an attempt to understand the various possible pathways, Goodman et al. developed a 
reaction prediction program named ROBIA (Reaction Outcomes By Informatics Analysis) 
capable of predicting the outcome of organic reactions given the starting materials and 
conditions.6 ROBIA was used to study the various cyclization manifolds that linear precursor 4 
may undergo. The proposed reaction pathway starting from 4 is hemi-acetal formation, retro-
Claisen, followed by hemi-acetal formation to furnish 1, therefore the transformations for each 
possible manifold would follow the same sequence. To begin, the linear precursor 4 was 
allowed to form any possible hemi-acetal disregarding any compounds containing four-
membered ring systems due to angle strain. ROBIA then transformed the two-dimensional 
structures into three-dimensional ones for calculations. The structures were minimized to give 
the most stable conformation resulting in 49 unique structures. Once the hemi-acetal was 
formed, the program allowed each unique structure to undergo a retro-Claisen rearrangement 
which resulted in a second set of intermediate structures (repeating conformational analysis 
and minimization of energy). These intermediates underwent a second hemi-acetal formation 
to produce the final set of structures. The previous sequence of filtering, generating all 
stereoisomers, transforming the structures into 3D, conformational analysis, and energy 
minimization were performed on all intermediates. 
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Scheme 1.4: Structures Predicted by ROBIA 
 Through the three reaction parameters, ROBIA generated 234 unique structures. Of all 
the structures determined, ROBIA concluded that the most stable stereoisomers are 
dolabriferol, its C-9 epimer (which would equilibrate to give dolabriferol), and three hemiortho 
esters shown in Scheme 1.4. Calculations put the esters higher in energy than the hemiortho 
esters, which are inconsistent both with experimental observations and higher levels of theory; 
hence, the hemiortho esters were discarded. These computational evaluations of the various 
cyclizations available to the acyclic precursor 4 suggest that the pathway to dolabriferol is 
thermodynamically favorable. Although these calculations support Gavagnin’s hypothesis for 
the formation of dolabriferol, proof requires direct evidence. Synthesis of the linear precursor 4 
would provide an opportunity to experimentally test Gavagnin’s hypothesis.  
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1.3. Synthetic Studies on Dolabriferol 
 Synthetic studies on dolabriferol have been reported by five groups with two successful 
total syntheses by Vogel and by Goodman. Three different synthetic approaches have been 
described in the literature to construct dolabriferol. 
 
Scheme 1.5: Retrosynthetic Approaches to Dolabriferol 
 The typical retrosynthetic design paradigm is to cleave the ester linkage forming the 
corresponding acid and alcohol moieties. The Dias and Chenevert approach allowed access to 
acid 6 and alcohol 7; however, neither group was able to esterify the two fragments.7,8,9 Lister 
and Perkins employed a retro-Claisen approach to obtain a protected derivative of dolabriferol 
but the deprotection was unsuccessful.10 Vogel reversed the sequence of reaction events by 
esterifying acid 8 and alcohol 9 first and delaying the formation of the lactol until the final step.5 
It is worth noting that the absolute configuration of dolabriferol was unknown until Vogel 
reported his synthesis in 2010. Looking back at the first attempts at the synthesis of 
dolabriferol, Dias and Lister/Perkins were using the incorrect enantiomers. If either of these 
routes had been successful, the product synthesized would have been ent-dolabriferol. Finally, 
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inspired by his calculations, Goodman completed the synthesis of dolabriferol via a retro-
Claisen approach.11  
1.3.1. Dias Route to Dolabriferol 
 Dias et al. tackled dolabriferol by conceptually cleaving the ester linkage to give acid 21 
and alcohol 16 with each of the two complex fragments being attainable from a common 
Weinreb amide precursor 12. The synthesis of 12 begins with a diastereoselective aldol addition 
of the boron enolate of acyloxazolidinone 10 with propionaldehyde furnishing 11 selectively. 
The corresponding Weinreb amide was formed and the hydroxyl group protected as its TBS 
ether to provide 12. Treatment of 12 with ethylmagnesium bromide formed ketone 13 which 
underwent aldol reaction with isobutyraldehyde followed by a syn-selective reduction to form 
the desired diol 14. Silyl deprotection of 14 followed by regioselective oxidation gave lactol 
fragment 16 in 8 steps (17% yield overall) starting from 10.  Synthesis of acid fragment 21 
started with reduction of Weinreb amide 12 to the corresponding aldehyde followed by Wittig 
homologation to give the desired α,β-unsaturated ester 17. Reduction of 17 with 
diisobutylaluminum hydride gave the corresponding allylic alcohol which was treated with m-
CPBA to form epoxide 18 as a single product. Epoxide opening of 18 was induced by reaction 
with Me2CuCNLi2 to give diol 19 that possessed the desired syn-anti-anti relative configuration 
for the four contiguous stereocenters. The final steps involved protection of the central 
hydroxyl as its PMB ether, deprotection of the silyl ether, and oxidation state adjustment to 
afford the desired acid fragment 21 in 13 steps (32% overall) starting from acyloxazolidinone 
10. Attempts to couple the two fragments to form the natural product were not reported.7 
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a) n-Bu2OTf, Et3N, propionaldehyde, DCM b) Me3Al, MeONHMe, HCl, THF c) TBSCl, imidazole, DMF d) EtMgBr, THF 
e) Cy2BCl, Et3N, isobutyraldehyde, DCM f) Zn(BH4)2, THF g) DOWEX-50, MeOH h) (COCl)2, DMSO, Et3N, DCM i) 
DIBAL-H, DCM j) Ph3PCHCO2Et, DCM k) DIBAL-H, DCM l) m-CPBA, DCM m) Me2CuCNLi2, THF n) PPTS, anisaldehyde 
dimethyl acetal, DCM o) DIBAL-H, toluene p) DOWEX-50, MeOH q) (COCl)2, DMSO, Et3N, DCN r) NaClO2, 2-methyl-
2-butene, Na2HPO4, 
t
BuOH  
 
Scheme 1.6: Dias Route to Dolabriferol 
 
 Although this route was close to completing the synthesis, the project had no new 
methodology, was a lengthy synthesis (24 steps total), and used an expensive starting material 
to form precursor 12. The project objectives were to provide a route to determine the absolute 
configuration of dolabriferol and to provide material for biological studies.  
1.3.2. Chenevert Route to Dolabriferol 
 Chenevert et al. were also able to synthesize alcohol 16 and acid 32 from a common 
precursor obtained via an enzymatic desymmetrization of 23 obtained by hydroboration of 
diene 22. Using vinyl acetate in the presence of Candida rugosa lipase resulted in 
enantioselective acylation of 23 to give 24 in high yield. Addition of intact molecular sieves to 
the medium was required to achieve high enantioselectivity by trapping acetaldehyde. Omitting 
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molecular sieves or using powdered molecular sieves caused enzyme deactivation. Once 
acylated, oxidation of the terminal alcohol in 24 gave aldehyde 25 which was treated with 
ethylmagnesium bromide to give 26 as a mixture of diastereomers. Oxidation of the mixture 
gave the desired acid fragment 32 in 6 steps (50% overall) starting from diene 22.8 
  
a) 9-BBN, NaOOH b) Candida rugosa lipase, vinyl acetate, hexane c) Dess-Martin periodinane, DCM d) EtMgBr, THF 
e) (COCl)2, DMSO, Et3N, DCM f) RuCl3, NaIO4, CCl4, H2O, MeCN g) TBAF, AcOH, THF h) TsOH, anisaldehyde dimethyl 
acetal, DCM i) KOH, MeOH j) Dess-Martin periodinane, DCM k) Mg(s), isopropyl bromide, THF l) Dess-Martin 
periodinane, pyridine, DCM m) LiAlH4, THF n) TBSOTf, 2,6-lutidine, DCM o) DIBAL-H, DCM p) Dess-Martin 
periodinane, pyridine, DCM q) EtMgBr, THF r) Dess-Martin periodinane, pyridine, DCM s) DDQ, H2O, DCM t) TBAF, 
AcOH, THF 
 
Scheme 1.7: Chenevert Route to Dolabriferol 
 
 With acid fragment 32 synthesized, formation of lactol 16 was pursued and envisioned 
to come from intermediate 24. Desilylation of 24, protection of the resulting 1,3 diol as its p-
methoxybenzylidene acetal, and base induced ester hydrolysis gave 27. Formation of aldehyde 
28 was achieved using Dess-Martin periodinane oxidation of 27 which was subsequently 
alkylated with isopropylmagnesium bromide yielding 29. The Grignard reaction unfortunately 
gave the undesired configuration at the C-3 stereocenter. The stereocenter was adjusted by a 
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simple redox sequence to give the desired 3-(S) configuration (10:1 dr). Silylation of 3-(S)-29 
with TBSOTf followed by DIBAL-H reductive acetal opening gave alcohol 30. Oxidation of 30 to 
the resulting aldehyde followed by Grignard reaction with ethylmagnesium bromide gave a 
diastereomeric mixture of alcohols, which upon oxidation, gave ketone 31. Finally, deprotection 
of the PMB ether and silyl ethers gave the desired hemiacetal 16 (16 steps from 22, 14% overall 
yield).9 There was no mention of attempted coupling of the two fragments to give dolabriferol. 
1.3.3. Lister and Perkins Route to Dolabriferol 
 Lister and Perkins discussed their attempts at coupling acid fragment 21 and alcohol 16 
but concluded that esterification was not possible under a variety of conditions. To overcome 
direct esterification, Lister and Perkins described a “biomimetic” retro-Claisen approach to form 
the desired ester linkage. The aldehyde 42 and ketone 38 were synthesized from 
stereocontrolled boron aldol reactions starting from the lactate derived 34. The (E)-enol 
dicyclohexylborinate of 34 was reacted with chiral aldehyde 33 to give 39 in excellent yield. The 
alcohol in 39 was protected as its TBS ether and subjected to SmI2 reductive benzoate removal 
to give 40. Reduction and protection of 40 using NaBH4 followed by PMB-imidate was required 
to avoid hemiacetal formation upon benzyl ether removal. Selective debenzylation of 41 with 
RANEY® nickel followed by oxidation furnished aldehyde 42. Ketone 38 was also prepared 
starting from intermediate 34. Reaction of the (E)-enol dicyclohexylborinate of ketone 34 with 
isobutyraldehyde gave ketone 35. After protection of the alcohol in 35 as its TBS ether, reaction 
with LiBH4 gave a 1,2 diol that was oxidatively cleaved to produce aldehyde 36. Coupling of the 
(E)-enol dicyclohexylborinate of ketone 34 with aldehyde 36 gave a single detectable adduct 37. 
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Protection of the newly formed hydroxyl in 37 as its TES ether, followed by SmI2 induced 
benzoate cleavage gave ketone 38.  
 
a) Cy2BCl, Me2Net, Et2O b) Cy2BCl, Me2NEt, isobutyraldehyde, Et2O c) TBSOTf, 2,6-lutidine, DCM d) LiBH4, THF e) 
NaIO4, MeOH, H2O f) Cy2BCl, Me2Net. Et2O g) TESOTf 2,6-lutidine, DCM h) SmI2, THF, MeOH i) TBSOTf , 2,6-lutidine, 
DCM j) SmI2, THF k) NaBH4, EtOH l) PMB-imidate, Et2O m) W2-RANEY® nickel, EtOH n) Dess-Martin periodinane, 
DCM o) LiHMDS, THF p) DDQ, DCM q) (COCl)2, DMSO, Et3N, DCM r) HF•pyridine/pyridine, THF s) DBU, C6D6 
 
Scheme 1.8: Lister/Perkin’s Route to Dolabriferol 
 The linear carbon chain 43 was prepared using a selective lithium aldol reaction to 
couple fragments 38 and 42, followed by PMB deprotection and a double oxidation using 
Swern’s protocol. Treating compound 43 with HF•pyridine/pyridine to remove the silyl ethers 
gave instead the doubly deprotected trioxaadamantane ring system 44. Exposure of 44 to DBU 
caused the tricylic system to collapse and undergo retro-Claisen rearrangement to give 45, a 
TBS protected derivative of dolabriferol (31% yield, 12 steps).10  
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 All attempts to deprotect 45 using various methods resulted in undesired products 
including elimination of hydroxyl groups and formation of spiroacetals which were non-
reversible. Although Perkins and Lister were unable to complete their synthesis, they provided 
a very elegant approach to the synthesis of dolabriferol and concluded that direct esterification 
of acid 21 and alcohol 16 was not a trivial transformation. 
1.3.4. Vogel’s Route to Dolabriferol 
 Vogel et al. overcame the problem of late stage coupling of the linear acid with the 
heterocyclic alcohol by reversing the order of steps. Using their reaction cascade, which 
combines electron-rich dienes and (E)-enoxysilanes through SO2 umpolung, allowed for rapid 
access to ,,-anti,anti-stereotriads in a one-pot reaction. Dolabriferol contains two ,,-
anti,anti-stereotriads which allowed both fragments to be assembled in similar fashion.5 It is 
worth noting that the starting dienes incorporate the inexpensive enantiomerically enriched 1-
arylethanol as a chiral auxiliary. The synthesis of the two anti,anti-stereotriads 48 and 54 
showcased the methodology developed by Vogel by providing six stereocenters selectively in 
two steps. Selective reduction of 48, Alloc protection of the resulting alcohol, and removal of 
the chiral auxiliary furnished the desired alcohol 51. 
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a) SO2, Tf2NH, DCM b) Pd(OAc)2, PPh3, iPrOHm MeCN, K2CO3 c) O3, DCM d) Me2S, H2O e) Me2AlCl, Bu3SnH, DCM f) 
allyl chloroformate, pyridine, THF g) TiCl4, DCM h) 2,4,6-trichlorobenzoyl chloride, Et3N, DMAP, toluene i) 
Bu3SnOMe j) KF, H2O k) CF3COOH, anisole, DCM l) Pd(OAc)2, Et2NH, TPPTS, MeCN/H2O 
 
Scheme 1.9: Total Synthesis of Dolabriferol by Vogel 
 
 Ozonolysis of 54 provided acid subunit 55 that was coupled with 51 using Paterson’s 
protocol yielding compound 56. Global deprotection of 56 induced cyclization to give 
dolabriferol 1 in 10 steps (7.9% overall) starting from diene 47. Vogel established the absolute 
configuration of dolabriferol through his synthesis, fifteen years after Gavagnin’s report.  
1.3.5. Goodman’s Route to Dolabriferol 
 Inspired by their calculations and the previous work of Lister and Perkins, Goodman et 
al. proposed the linear precursor should cyclize to give dolabriferol as the thermodynamically 
more stable compound. To synthesize the carbon skeleton of 67, a Sn(OTf)2 mediated aldol was 
envisioned to couple fragments 62 and 66. These two fragments were assembled starting from 
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Evans’ -ketoimide 10 and diol 63 synthesized using MacMillan’s organocatalytic cross-aldol 
methodology.  
 
a) EtCOCl, LDA, MgBr2•Et2O, THF b) TiCl4, DIPEA, EtCHO, DCM c) Me4NBH(OAc)3, AcOH, MeCN d) anisaldehyde 
dimethyl acetal, TsOH e) LiBH4, MeOH, THF f) (COCl)2, DMSO, Et3N, DCM g) anisaldehyde dimethyl acetal, TsOH h) 
DIBAL-H, DCM i) (COCl)2, DMSO, Et3N, DCM j) Cy2BCl, Et3N, DCM k) TESOTf, 2,6-lutidine, DCM l) SmI2, THF, MeOH 
m) Sn(OTf)2, Et3N, DCM n) Dess-Martin periodinane, NaHCO3, DCM o) HF•pyridine/pyridine, THF p) DBU, benzene 
q) CSA, MeOH r) Dess-Martin periodinane, NaHCO3, DCM s) DDQ, pH buffer 7, DCM 
 
Scheme 1.10: Total Synthesis of Dolabriferol by Goodman 
 Addition of propionyl chloride to the lithium enolate of oxazolidinone 10 gave the 
desired β-ketoimide 58 in high selectivity (24:1). Generation of the titanium enolate of 58 and 
subsequent addition of propionaldehyde smoothly afforded 59. Hydroxy directed reduction of 
59 furnished the 1,3-anti-diol 60 that was subsequently protected as the anti-PMP acetal 61. 
Cleavage of the auxiliary using LiBH4 gave the corresponding alcohol which upon oxidation gave 
aldehyde coupling partner 62. Synthesis of ketone 66 started from PMP acetal formation from 
diol 63, followed by regioselective reductive cleavage of the PMP acetal with DIBAL-H, and 
subsequent oxidation of the resulting alcohol gave the desired aldehyde 64. Addition of 
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aldehyde 64 to the (E)-enol dicyclohexylborinate of 65, protection of the newly formed hydroxyl 
as its TES ether, followed by SmI2 mediated cleavage of the benzoate afforded ketone coupling 
partner 66.  
 Coupling of fragments 62 and 66 was achieved via the tin enolate of 66 yielding a 
mixture of aldol adducts in high yield (83%, 12.6:1 dr). Oxidation of the aldol adducts with Dess-
Martin periodinane gave 67 with no evidence of the enol tautomer by 1H NMR and no observed 
epimerization at the C-8 stereogenic center. With 67 in hand, deprotection of the TES ether 
unveiled a hydroxydiketone precursor for retro-Claisen rearrangement. Adopting the conditions 
from Lister and Perkins, exposure of the hydroxy-diketone to DBU effected the desired 
transformation to give 68 as the only product in high yield. With the ester linkage in place, all 
that remained was hydrolysis of the PMP acetal, chemoselective oxidation of the C-3 hydroxy 
group, and PMB removal to give dolabriferol.11 Goodman’s synthesis provided the desired 
product in 14 steps from propionaldehyde in 4% overall yield in the longest linear sequence. 
Although Goodman was able to form dolabriferol via a retro-Claisen approach, the precursor 
still contains protecting groups and is not in the correct oxidation state. This demonstrated that 
compounds like 67 undergo rearrangement under mild base but did not shed light on the origin 
of dolabriferol.  
1.4. Conclusion 
 The above approaches towards the synthesis of dolabriferol show that the synthesis of 
the target molecule is challenging. Forming the ester linkage between the two final fragments 
being unsuccessful with the methods tested. Although the route by Vogel is elegant and 
allowed for the absolute configuration to be determined, the question still remains if the acyclic 
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precursor is on the biosynthetic pathway and if cyclization is induced non-enzymatically. The 
route by Lister and Perkins through 44 shows promise as a feasible precursor to dolabriferol. 
Allowing the compound to cyclize allows for internal protection to the more robust 
trioxaadamantane. This highly unusual ring system has been identified in only two siphonariid 
natural products: muamvatin12 and caloundrin B13, both of which have been synthesized by the 
Ward group. The methodology developed in the group should allow for formation of an 
intermediate similar to 44 and may be exploited to access a route to dolabriferol through its 
acyclic intermediate 4. 
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RESULTS AND DISCUSSION 
2.1. Research Objectives 
Within the Ward group, a recent strategy for polypropionate synthesis involves 
preparation of the linear precursor of certain polypropionate natural products and studying 
their cyclization patterns. So far, baconipyrone A, baconipyrone C, siphonarin B, and muamvatin 
have been synthesized from their putative ‘acyclic’ precursors suggesting that perhaps these 
acyclic precursors are the biosynthetic products (Scheme 2.1).3,14 This implies that many 
isolated polypropionates may not be the products formed during the biosynthetic pathway but 
are instead artifacts of isolation; i.e., the cyclizations and/or rearrangements are not induced 
enzymatically. 
 
a) imidazole b) aluminum oxide activated basic 
Scheme 2.1: Synthesis of Polypropionates Through Their Putative Precursors  
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 Of the possible pathways to form dolabriferol, a retro-Claisen approach was chosen to 
test if the linear precursor is the biosynthetic product. Therefore, the synthesis of precursor 4 
should be the primary focus and, if achieved, may shed light on the origin of dolabriferol. The 
extensive methodology developed in the Ward group provides a precedent to synthesize 
contiguous carbon frameworks with control over the stereocenters being formed. Along with 
the preparation of the linear precursor, a method to perform an aldol reaction proceeding with 
kinetic resolution where the aldehyde is the enantioenriched fragment (and limiting in the 
reaction) was contemplated, a reaction not done before within the thiopyran route to 
polypropionates.  
2.2.  The Thiopyran Route to Polypropionates 
 The thiopyran route to polypropionates has been a core research theme in the Ward 
group for over a decade and allows for rapid access of various tetrapropionate (4 diastereomers 
of 76) and hexapropionate (20 diastereomers of 77) precursors stereoselectively. These 
complex starting materials are prepared in a few steps from starting ketone 75 and aldehyde 74 
which themselves are prepared in a few steps and in high yield.15 This route begins with 
commercially available diester 70 which is prepared from inexpensive methyl acrylate 69 and 
sodium hydrosulfide.16 Dieckmann cyclization of 70 with sodium methoxide gives β-ketoester 
7117 which is subsequently subjected to acetal protection, lithium aluminum hydride reduction, 
and oxidation with IBX to yield the desired aldehyde 74.18 Preparation of ketone 75 is achieved 
by decarboxylation of 71 under acidic conditions to give the desired compound as a free flowing 
white solid.17 These steps provide 74 and 75 in pure form without chromatography and can be 
done on large scale (>40g for 74 and >200g for 75). Aldol coupling of ketone 75 and aldehyde 74 
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has been extensively studied and all four diastereomers of 76 (referred to as “mono-aldols”) 
are available in high yield and enantiopure form.19  
  With rapid access to the four diastereomers of 76, it seemed feasible that aldol 
coupling with a second equivalent of aldehyde 74 could furnish 77 providing a general strategy 
to rapidly assemble stereochemically complex hexapropionate synthons derived from simple 
starting materials. After extensive study, access to all twenty diastereomers of 77 (referred to 
as “bis-aldols”) was possible by varying the reaction conditions to favor the desired 
diastereomer, however, the compounds prepared were racemic.20,21 To obtain a single 
enantiomer the reaction would require either coupling of two enantioenriched fragments or 
coupling of one enantioenriched fragment to a racemic fragment through kinetic resolution. In 
a simple sense, kinetic resolution is the result of a difference in reaction rates of enantiomers in 
a chiral environment and exploiting this phenomenon could allow for assembly of 
enantioenriched hexapropionate synthons from racemic aldehyde 74.     
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a) NaHCO3 b) Na, MeOH c) ethylene glycol, TsOH (cat.), benzene, reflux d) LiAlH4, THF e) IBX, MeCN f) 10% H2SO4, 
reflux g) ref 16 h) ref 17 & 18 i) ethylene glycol, TsOH (cat.), benzene, reflux j) NaOH, H2O, MeOH k) (COCl)2, 
benzene l) thiophenol, Et3N, THF m) s-BuLi then (-)-82, THF n) LiAlH4, THF o) Dess-Martin periodinane, H2O, DCM p) 
MeLi q) TESOTf, pyridine, DCM r) (S)-85 (20 mol%), wet DMSO s) TESOTf, pyridine, DCM t) BCy2Cl, Et3N, DCM 
 
Scheme 2.2: Thiopyran Route to Polypropionates and Kinetic Resolution 
 
 Knowing the developed aldol coupling methodology was moderate to highly 
diastereoselective depending on the reaction conditions, it can be predicted that using 
enantioenriched diastereomers of 76 should give the same adducts but in enantioenriched 
form with similar diastereoselectivites to those observed (using racemic diastereomers of 76). 
All four diastereomers of 76 were prepared in enantioenriched form and tested to validate the 
prediction.20,21 In each case, the desired diastereomer was obtained with similar 
stereoselectivity while maintaining the enantiomeric excess in the starting material 76 (e.g., 
aldol coupling of ketone 78 with aldehyde 74 gave enantioenriched bis-aldol 79).20 The same 
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concept should apply if aldehyde 74 was prepared in enantioenriched form and coupled to 
racemic ketone 78 (an unprecedented reaction within the thiopyran route).  
 The thiopyran route to polypropionates provides a simple and scalable protocol to 
produce starting material quickly with minimal chromatography. This is crucial for maintaining 
progress in a target directed synthetic project since a good deal of time can be required if 
starting material synthesis is difficult. The diastereomers of 76 have been extensively studied in 
aldol reactions providing the desired precedent for comparison when different chiral aldehydes 
are employed. Although this route provides a method for constructing polypropionate based 
frameworks effectively (and has been used in the synthesis of a number of natural 
products),3,14,22 application to natural products still poses quite a challenge.  
2.3.  Synthetic Considerations 
 The synthesis of the acyclic precursor 4 requires control of the relative configuration of 
the eight stereocenters. The configuration must also be controlled in an absolute sense since an 
enantioenriched product is desired. Control over the stereochemical outcome and construction 
of the carbon backbone can be achieved using existing methodologies within the thiopyran 
route to polypropionates. To obtain a single enantiomer the synthesis will require coupling of 
two enantioenriched fragments or coupling a racemic fragment with an enantioenriched 
fragment via kinetic resolution. Exploitation of one of these methods should provide the means 
to tackle the complexity of dolabriferol. 
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Figure 2.1: Structural Features of Dolabriferol and its Linear Precursor 
 Taking a closer look at the structures of both dolabriferol and its linear precursor unveils 
functional groups that may be difficult to handle. Dolabriferol contains a six-membered lactol 
and a polypropionate fragment both known to undergo elimination under acidic conditions. 
The ester linkage can be cleaved under basic conditions. Although these reactions are possible, 
they require quite harsh conditions to occur. The linear precursor 4 is much more sensitive and 
difficult to handle. The position at C-8 is located between two ketones making the hydrogen 
located there quite acidic and easy to epimerize. Handling diketones, in general, makes the 
characterization and purification difficult since they are usually an equilibrating mixture of 
tautomers. The 5-hydroxy-3,7,9-triketone motif is very prone to decompose under acidic 
conditions (elimination) and under basic conditions (retro-Claisen). Revealing this complex 
moiety will need to be done at a late stage and under mild conditions to prevent side reactions 
from occurring. 
2.4.  Retrosynthetic Analysis 
 In order to test the hypothesis of the origin of dolabriferol, access to the linear 
precursor is crucial. The effort by Lister and Perkins to form dolabriferol via the 
trioxaadamantane intermediate is particularly intriguing from a synthetic standpoint. 
Incorporating this tricyclic moiety may provide a very concise solution to the total synthesis of 
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dolabriferol that can overcome the problems encountered in previous attempts. The 
trioxaadamantane ring system would act as an internal protection of the sensitive 5-hydroxy-
3,7,9-triketone. 
 
a) Cy2BCl, Et3N b) IBX c) FeCl3•6H2O d) RANEY® Nickel e) imidazole  
Scheme 2.3: Formation of Trioxaadamantane Ring System 
 The trioxaadamantane ring system has only been identified in two natural products to 
date: muamvatin12 and caloundrin B13, both of which have been synthesized in the Ward group 
providing precedent on their formation. Starting from ketone 86, a simple aldol with propanal, 
oxidation of the newly formed hydroxyl, and mild deprotection is required to reveal the desired 
5-hydroxy-3,7,9-triketone 89.23 Under thermodynamic control, compound 89 undergoes ring-
chain tautomerism forming the dithiapentacycle 90.23 Subjecting 90 to RANEY® nickel removes 
the sulfur atoms producing compound 91 containing a destabilizing syn-pentane interaction.23 
Allowing this thermodynamically unstable compound to isomerize in the presence of imidazole 
provides the desired ring system 92 exclusively.23  
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 Because the trioxaadamantane ring system is also unstable, its formation would have to 
be induced at a late stage in the synthesis. Knowing that the ring system can be formed using 
the thiopyran route, the main focus of the synthesis would be on preparing the 
trioxaadamantane ring system to form the internally protected 93 known to be less susceptible 
to side reactions compared to 94 (Scheme 2.4). Once prepared, the tricyclic system would be 
subjected to mild basic conditions (eg. DBU) to induce the expected retro-Claisen 
rearrangement. The protecting group selection is crucial for the formation of acyclic precursor 
4. The hydroxy protecting group at C-5 must be orthogonal to the hydroxy protecting groups at 
C-11 and C-13, as this allows control in the deprotection strategy if the acyclic precursor 4 fails 
to cyclize to give dolabriferol. By leaving strategic protecting groups in place, the compound 
could be orchestrated to cyclize in the desired fashion.  Using benzyl ethers as the protecting 
group at C-11 and C-13 would allow these groups to remain unchanged as a silyl ether at C-5 
and acetal are deprotected under mild acidic conditions. This should unveil the desired 5-
hydroxy-3,7,9-triketone which would cyclize to 93. The benzyl ethers and the sulfur atoms 
could be removed using RANEY® nickel to produce the acyclic precursor 4 along with its ring-
chain tautomeric forms.  
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Scheme 2.4: Retrosynthetic Analysis 
 Disconnection of the C-8 and C-9 bond in 94, leads to ketone 95 and aldehyde 96 as 
desired precursors (Scheme 2.4). The disconnection here is beneficial for synthetic reasons in 
the forward coupling sequence. The aldol coupling of ketone 95 and aldehyde 96 represent a 
matched pair and should give high diastereoselectivity resulting in one diastereomer 
predominately. Oxidation of the newly formed hydroxyl at C-9 in the aldol adduct would 
produce diketone 94. The C-8 position can now be easily epimerized creating an equilibrating 
mixture of diketones and their enol form. Upon deprotection, 94 should cyclize to the 
trioxaadamantane 93. An ongoing theme within the Ward group is the development of 
reactions that proceed with kinetic resolution.3,20 This approach to coupling chiral fragments 
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presents a powerful tool that is usually overlooked. Since both ketone 9824 and aldehyde 96 can 
be prepared in enantioenriched form via the thiopyran route to polypropionates, the selection 
of which compound will be enantioenriched is based on their relative ease of preparation. 
Aldehyde 96 was thought to be much easier to prepare in enantiomerically enriched form 
starting from a proline catalyzed aldol reaction between ketone 75 and isobutyraldehyde.25 
Ketone 98 is readily available in racemic form via a Mukaiyama aldol between 74 and the TMS 
enol ether 84. If any problem arose from the thiopyran based ketone 98, a simple alternative 
would be to desulfurize compound 98 to furnish ketone 99 (now capable of Z-enolate 
formation). If ketone 99 showed promising results, compound 99 could be prepared from 100 
and 101 using existing methodology in the Ward group coined as the “Acyclic Route to 
Polypropionates”.26 
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2.5. Building the Fragment Analogues that Nature Makes Look Easy 
2.5.1. Enantiomeric Excess from Nature to Laboratory  
 The synthesis of enantiopure aldehyde 96 begins with a proline mediated aldol reaction 
between tetrahydrothiopyran-4-one 75 and isobutyraldehyde, that provides the desired aldol 
adduct 97 with high diastereo- and enantioselectivity.25 The synthesis of diol 111 and 112 has 
previously been accomplished by Pramod Jahdav, a former Ward group member.27 The 
discussion hereafter, will be covering optimization of the synthetic sequence up to compounds 
111 and 112, isomerization of 111 into 112, and the synthesis of the desired aldehyde fragment 
96. 
 
a) TES-Cl, Et3N, DCM b) 
t
BuLi, then methyl cyanoformate, THF c) 5% HF, MeCN d) Et2BOMe, NaBH4, THF:MeOH (4:1) 
 
Scheme 2.5: Early Stage Preparation of Enantioenriched Aldehyde 
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 The use of (S)-proline allows for achiral ketone 75 to be transformed into the 
corresponding enantiopure enamine 103 which then reacts with isobutyraldehyde through two 
possible transition states, TS-104 or TS-105. In TS-105, reaction of the si face of the aldehyde 
orients the large group above the ring system causing steric clash which is an unfavorable 
interaction resulting in slow formation of 106. In contrast, addition to the aldehyde’s re face via 
TS-104 minimizes this steric repulsion by placing the smallest group above the ring. The energy 
required to reach TS-104 is lower than TS-105 and this difference in energy dictates the 
diasteromeric ratio formed; in this case a greater than 20:1 mixture of the desired compound 
97. The transition states with the enamine oriented anti relative to the carboxylic acid and 
alkene are favored over the syn relative orientation. This orientation preference and 
intermolecular hydrogen bonding selects one face of the ketone to react predominately. Since 
the two faces of the ketone are not equivalent, the result is an enantioenriched product. 
 Aldol adduct 97 was protected as its corresponding silyl ether 107 by reaction with 
triethylsilyl chloride and triethylamine. With compound 107 in hand, a direct deprotonation 
was performed with tBuLi to form the lithium enolate which underwent carbonylation with 
Mander’s reagent (methyl cyanoformate) to give an equilibrating mixture of β-ketoesters 108.27 
The silyl ether in 108 was removed by treatment with hydrofluoric acid to give 109 as a mixture 
of β-ketoesters along with its enol form.27 Syn-selective reduction of 109 with 
diethylmethoxyborane and sodium borohydride produced a 1:1.5 mixture of syn diols 111 and 
112, respectively. The desired 2,3-trans diol 112 was separated by column chromatography and 
carried through subsequent reactions. An interesting observation was noted when potassium 
hydride was added to 111 during an attempted double benzyl protection.27 Under these 
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conditions, 111 underwent isomerization at C-2 giving the desired compound 112 as the only 
product. Exploiting this phenomenon could provide a convergent synthesis to the desired 2,3-
trans diol 112 from a mixture of 111 and 112.  
2.5.2. Isomerization Studies 
 The isomerization under excess potassium hydride is not a known method to converge a 
mixture of 3-hydroxyesters to a single diastereomer. Presumably the mixture 113 can undergo 
two pathways for isomerization: enolate formation followed by selective protonation to give 
112; a retro-aldol to break the thiopyran template forming the acyclic enolate 117 which then 
undergoes selective aldol addition. In both routes the mixture is transformed into the 
presumed more thermodynamically stable, 2,3-trans compound 112 which has all substituents 
of the chair in equatorial positions.   
 
Scheme 2.6: Possible Routes to Isomerization 
 The use of potassium hydride as the base was found to be troublesome, with reactions 
requiring an excess (2-3 equivalents) most likely due to the low solubility of potassium hydride 
in ethereal solvents. On small scale (<20 mg of starting material), the reaction of 113 produced 
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112 rapidly and in high yield (Table 2.1, entry 1). However, trying to scale the reaction to 
anything larger (>100 mg, Table 2.1, entry 2), resulted in incomplete isomerization or 
decomposition to an unidentified compound. Puzzled by these results, the base was switched 
from potassium hydride (insoluble in THF) to the more soluble potassium hexamethyldisilazide 
(KHMDS). Using KHMDS allowed for control of the amount of base in solution, and could 
possibly remove the requirement of excess base noted in the preliminary results. 
 The reaction of 113 with KHDMS at decreased temperature allowed the isomerization to 
occur effectively (Table 2.1, entry 3-5). A sample of the 2,3-trans compound 112 was stable to 
the reaction conditions (Table 2.1, entry 6). Despite success on small scale, scaling the reaction 
to anything larger (>100 mg) again resulted in partial isomerization requiring more base to 
complete or, in most cases, decomposition to unidentified byproducts. Despite failure on a 
larger scale, the results showed promise that the difference in energy between 2,3-cis and 2,3-
trans can be exploited to isomerize the mixture 113 to the required compound 112 on the 
pathway to dolabriferol. This problem was extensively studied by Naveen Diddi, a colleague in 
the Ward group.28 
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Table 2.1: Optimized Isomerization Results 
 
 
Entry 
 
SM 
 
Conditions (Base) 
Product Distribution (%)a 
111 112 118 120 121 
 113 KH, 0 oC, 2 h      
1 100 mg 3 equiv. 
3 equiv. 
 100%    
2 450 mg 30% 70%    
  KHMDS, -78 oC, 1 h      
3 113 1 equiv. 38% 62%    
4 113 2 equiv. 25% 75%    
5 113 3 equiv. 18% 82%    
6 112 2 equiv.  100%    
7 111 2 equiv. 25% 75%    
  NaH, 0 oC, 24 h      
8 111 2 equiv.     100% 
  KOtBu, Et2O      
9 111 2 equiv.  80%b    
10 119 2 equiv.    76%b  
  KOtBu, CuI, Et2O      
11 111 2 equiv.  85%b    
12 113 2 equiv.  61%b    
13 119 2 equiv.    93%b  
a By 1H NMR spectroscopy unless otherwise indicated b Isolated yield 
 Having demonstrated that the desired transformation to streamline the synthesis was 
possible, the base was switched to potassium tert-butoxide.28 Using a base that is capable of 
deprotonating secondary alcohols but not basic enough to form a substantial amount of 
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enolate may simplify the problem. Subjecting the 2,3-trans 111 to these new conditions gave 
the desired 112 in reasonable yield (80%) with a very polar impurity accounting for the rest of 
the material (Table 2.1, entry 9). With prolonged reaction times, 112 was eventually largely 
transformed into a polar material which was later identified as the corresponding carboxylic 
acid 121. Adding copper(I) iodide to the reaction media suppressed hydrolysis and produced 
112 in high yield (85%, Table 2.1, entry 11).28 However, exposing the mixture of isomers 113 to 
the same conditions resulted in lower yield (61%) and a substantial amount of compound 121 
(Table 2.1, entry 12). Switching to the benzyl ester analogue 119, decreased the rate of ester 
hydrolysis resulting in an excellent yield of the corresponding 120 in a scalable procedure 
(Scheme 2.8).28  
a) (S)-proline, DMSO b) TES-Cl, Et3N, DCM c) 
t
BuLi, then benzyl cyanoformate, THF d) 5% HF, MeCN e) 
t
BuLi, then 
methyl cyanoformate, THF f) 5% HF, MeCN g) Et2BOMe, NaBH4, THF:MeOH (4:1) h) KO
t
Bu, CuI, Et2O i) Et2BOMe, 
NaBH4, THF:MeOH (4:1) j) KO
t
Bu, CuI, Et2O k) dimethoxyphenylmethane, TsOH, DCM l) LiAlH4, THF m) oxalyl 
chloride, DMSO, Et3N, DCM 
 
Scheme 2.7: Overview on the Synthesis of Enantioenriched Aldehyde  
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 With the desired esters 112 or 120 in hand, the next step involved protection of of the 
1,3 diol. As mentioned in the retrosynthetic analysis, the strategy was to protect the diol with a 
group orthogonal to the protecting group on the ketone fragment (in this case a BOM or silyl 
ether group). The protecting group would also need to be labile under mild conditions. With 
these required criteria, benzyl ethers or a benzylidene acetal were chosen as possible 
protecting groups, both removable by hydrogenolysis. The predominant method for protecting 
alcohols as benzyl ethers is to subject the starting material to strong base in the presence of 
benzyl bromide. As described above,  112 is unstable to strongly basic conditions typical for 
alcohol benzylation. If direct benzylation was to be pursued, the reaction would need to be 
done under conditions where isomerization would be supressed; i.e. not strongly basic media. 
Within the literature, other methods have been developed to synthesize benzyl ethers in 
neutral29 and acidic media30. Of these methods, none gave the desired dibenzyl ether protected 
ester of 112/120 but instead resulted in no reaction or decomposition of the starting material. 
Switching to the formation of the benzylidene acetal resulted in a promising alternative, the 
1,3-cis diols 112 or 120 could be protected using dimethoxyphenylmethane and reduced to give 
alcohol 123 (Scheme 2.7). Finally, oxidation of 123 using Swern’s protocol gave the desired 
aldehyde fragment 124 in excellent yield. The synthesis of alcohol 123 via 122 has been 
optimized by Naveen Diddi, a colleague in the Ward group.28    
2.5.3. Synthesis of Racemic Ketone 
 As mentioned earlier, the synthesis of tetrapropionate fragments via the thiopyran 
route has been highly optimized for rapid access on multi-gram scale.20 The route begins with 
diketoester 70 which undergoes Dieckmann cyclization to form the cyclic β-keto-ester 71 
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(Scheme 2.9). From here the syntheses of the aldehyde 74 and silyl enol ether 84 diverge. 
Subjecting β-keto-ester 71 to acidic media for decarboxylation followed by treatment with 
TMS-Cl and triethylamine gave silyl enol ether 84. Treatment of 71 with ethylene glycol in the 
presence of acid gave the corresponding protected ester 72. Reduction of 72 with LiAlH4 
followed by oxidation with IBX in acetonitrile afforded aldehyde 74.  
 
a) Na, MeOH b) ethylene glycol, TsOH, benzene, reflux c) LiAlH4, THF d) IBX, MeCN e) 10% H2SO4, reflux f) TMS-Cl, 
TEA, CHCl3 g) MgBr2•OEt2, DCM h) imidazole, DCM i) MOM-Cl, DIPEA, DCM j) BOM-Cl, DIPEA, DMF k) TES-OTf, 2,6-
lutidine, DCM l) TBS-OTf, 2,6-lutidine, DCM 
 
Scheme 2.8: Preparation of Various Protected anti-anti Ketones 
 Silyl enol ether 84 and aldehyde 74 were subjected to Mukaiyama aldol conditions in 
the presence of MgBr2•OEt2 to form a mixture of syn-anti 125 and anti-anti 98 in a 3:1 ratio 
respectively.20 Aldol adduct 125 could be isolated by fractional crystallization in methanol 
leaving the mother liquor containing a 6-10:1 mixture of 98 and 125 respectively. The mixture 
of aldol adducts was separated by column chromatography giving the desired anti-anti aldol 98. 
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Subjection of 125 to imidazole induced isomerization to provide a 2:1 mixture of 125 and 98 
respectively.20 The process of fractional crystallization and separation by column 
chromatography can be repeated in several cycles in order to access the less 
thermodynamically stable 98. Finally the free alcohol was protected as its corresponding MOM, 
BOM, TES, and TBS ether to furnish (±)-8621, (±)-126, (±)-12721, and (±)-128 respectively. 
2.5.4. Kinetic Resolution and Exploitation of the Principle 
 With aldehyde 124 and several ketone candidates in hand, the next challenge requires a 
selective aldol coupling of these two fragments. Directing the stereochemical outcome of the 
aldol reaction can be difficult and may result in a mixture of products if stereoselectivity is not 
high. Traditionally, coupling of two enantioenriched fragments is employed to simplify the 
problem by decreasing the number of possible aldol adducts formed. Although this method is 
very effective, it requires the synthesis of two enantiopure coupling partners where each can 
be difficult to prepare, expensive, and require more steps to prepare than their racemic 
counterparts. To overcome some of these issues, an underutilized synthetic approach involves 
coupling of an enantioenriched fragment with a racemic fragment via kinetic resolution. Kinetic 
resolution is defined as a process where enantiomers have unequal reactivities in the presence 
of a chiral agent (reagent, catalyst, solvent, etc.). The development of coupling reactions that 
proceed with kinetic resolution is an ongoing theme in the Ward group, where convergent 
coupling of chiral fragments through aldol reactions has shown great application in natural 
product syntheses.3,23 
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Scheme 2.9: Demonstration of Kinetic Resolution with Racemic Aldehyde 
 In one of numerous examples from the Ward group (Scheme 2.9), kinetic resolution is 
shown utilizing ketone 129 (similar ketone proposed in the synthesis of dolabriferol).21 
Reactions of racemic ketones (such as 129) with racemic aldehydes (such as 74) can result in 
eight possible racemic aldol adducts.  The stereoselectivities of such reactions can be factorized 
into three stereocontrol elements: i) diastereoface selectivity of the enolate, ii) diastereoface 
selectivity of the aldehyde, and iii) the relative topicity of the aldol coupling. As long as all three 
of these elements are highly biased, predominately one aldol adduct will be formed. Reaction 
of the boron enolate (Cy2BCl, TEA) of (±)-129 with (±)-74 gave racemic trans-anti-Felkin adduct 
130 selectively (dr 18:1, 80% yield). This result suggests that reaction of the (3R)-enantiomer of 
129 with the (6R)-enantiomer of 74 is highly diastereoselective and much faster than the 
alternative reaction with (6S)-74 (Similarly, (3S)-129 must react preferentially with (6S)-74). By 
substituting the racemic ketone with its enantioenriched counterpart 129 (91% ee), reaction 
with (±)-74 under identical conditions, should give diastereomer 130 with similar 
diastereoselectivity but the products will be enantioenriched. As predicted, reaction of (+)-129 
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(91% ee) with (±)-74 under these conditions resulted in preferential coupling with (6R)-74 to 
give aldol adduct (-)-130 selectively (dr 14:1, 74% yield, 91% ee).21 Applying the same concept 
to couple fragments 95 and 124 should, in theory, follow the same paradigm where varying the 
reaction conditions should select the correct enantiomer of racemic ketone 95 to react 
preferentially with enantioenriched aldehyde 124. 
 
Scheme 2.10: Proposed Aldol Coupling for Dolabriferol 
 The illustrated example (Scheme 2.9) and proposal for dolabriferol (Scheme 2.10) 
demonstrate the application of kinetic resolution but do not explain how kinetic resolution 
works and what is required for a successful reaction. Kinetic resolution works by irreversibly 
differentiating a pair of enantiomers due to differences in activation energies. While both 
enantiomers of a racemate (in this case the ketone/enolate 95) are at the same energy level 
(Figure 2.2), the presence of an enantioenriched reactant, such as aldehyde 124, generates two 
diastereomeric aldol transitions states at different energies (TS2R vs TS2S). The difference in 
these competing transition state energies (ΔΔG‡) defines the ratio of rate constants for the fast-
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reacting and slow-reacting enantiomers, and this ratio (kfast/kslow, defined as stereoselectivity 
factor, or S) controls the product distribution.   
 
Figure 2.2: Energy Diagram of a Reaction Proceeding with Kinetic Resolution 
 
 Due to the fact that two enantiomeric species are reacting simultaneously at different 
rates, the relative concentrations of SMR/SMS and AldolR/AldolS are changing as the reaction 
proceeds and, as a consequence, the enantiomeric composition of the starting material and the 
stereoisomeric composition of the product become a function of conversion. Not surprisingly, 
the larger the difference in reaction rates (larger value of S), the more selective the reaction is. 
However, when using a stoichiometric ratio of reactants the selectivity diminishes with reaction 
conversion, eventually becoming unselective regardless of the selectivity factor (S) (Figure 2.3). 
This phenomenon is due to depletion of the fast reacting enantiomer in the early stages of the 
reaction leaving a higher concentration of the undesired enantiomer to react. Therefore, in 
order to maintain high selectivities, the racemic reactant is used in excess thereby maintaining 
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a high concentration of the fast reacting enantiomer. Consequently, the reaction is stopped at 
low conversion with respect to the racemate but high conversion with respect to the 
enantioenriched fragment. Although using a very large excess would provide the maximum 
selectivity, practically, purification of the product from a large excess of racemate can be 
difficult. In the Ward group, an excess of three equivalents is usually used which sacrifices some 
selectivity but keeps purification relatively straightforward. 
 
Figure 2.3: Effect of Selectivity Factor on Stereoisomeric Excess 
 The concept of an aldol reaction proceeding with kinetic resolution is exactly the same 
regardless of which fragment is racemic and which is enantioenriched. Although Figure 2.3 
sheds light on reaction design, the equations used assume pseudo first-order kinetics for the 
substrate and does not account for nonlinear effects. Within the thiopyran route, the aldehyde 
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has always been the racemic fragment due to its ease in preparation. For the proposal strategy 
in the synthesis of the linear precursor 4, the ketone will be the racemic fragment, i.e. needs to 
be used in excess. This reversal of reactant roles is unprecedented and worth studying for its 
applicability in natural product synthesis. This may however require a different approach of 
optimization with the reversal of the reactant used in excess.  
2.6. Aldol Studies 
2.6.1. Thiopyran Based Ketones as Aldol Coupling Partners 
A potential concern with the aldol fragment coupling within the thiopyran route to 
polypropionates is the amount of reagent needed to generate the enolate. For most of the 
thiopyran based ketones, an excess of reagent is required to achieve high conversion.  The 
excess reagent remaining after enolization can consume the aldehyde by undergoing undesired 
reactions. When the aldehyde is used in excess, any such decomposition does not affect the 
reaction outcome. The synthetic plan for dolabriferol is quite the opposite, excess ketone with 
excess enolizing reagent may react with the limiting aldehyde and, consequently, reduce the 
overall yield of the desired aldol adduct. The aldol coupling of ketone 95 with 74 (3 equiv.) using 
Cy2BCl and Et3N to generate the enol borinate has been heavily optimized to give the 
corresponding bis-aldol 134 in good yield with excellent diastereoselectivity (Table 2.2, entry 
1).21 When the same reaction was conducted with one equivalent of BCy2Cl, the yield of 134 
decreased to 35% (Table 2.2, entry 2) and using stoichiometric amounts of 74 did not produce 
the adduct 134 (Table 2.2, entry 3). However, as mentioned earlier, the reaction requires two 
equivalents of BCy2Cl to proceed in high yield. 
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Table 2.2: Effect of Aldehyde and Mediator Equivalents on Reaction Yield 
 
Entry Ketone 
(1 equiv.) 
Equiv. 74 Equiv.  
BCy2Cl 
Equiv. 
tBuNH2 
Product (yield, dr) 
1 86 3 2 0 134 (80%, 13:1) 
2 86 3 1 0 134 (35%, 13:1) 
3 86 0.5 2 0 No Reaction 
4 127 3 2 0 135 (87%, 10:1) 
5 127 0.50 2 2 135 (83%,10:1) 
 
Thus, having the ketone in excess and the aldehyde limiting (conditions required for the 
proposed dolabriferol synthesis) is not suitable for aldol reaction via the enol borinate. This 
problem is not resolved by reducing the amount of BCy2Cl used. A potential solution to this 
problem is to “quench” any excess BCy2Cl prior to aldehyde addition to prevent decomposition 
of the aldehyde. A method would need to be developed where quenching of the excess borane 
reagent would not also cause quenching of the borane enolate. It is known in the literature that 
BPh2Cl reacts with primary or secondary amines to form aminoboranes in moderate to high 
yield.31 Of particular interest is the use of primary amines, such as tert-butyl amine. Although 
the reaction gave the highest yield when the mixture was refluxed, the reaction could be 
performed at lower temperatures (-50oC). For the proposed application, it is crucial the reagent 
is able to quench the borane at low temperatures because the enol borinate is not stable at 
elevated temperatures. As shown, enolization of ketone 127 follows the standard conditions 
within the Ward group of using excess borane to achieve high conversion for enolate formation 
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(Table 2.2, entry 4). The excess borane remaining is reactive towards aldehydes causing an 
unwanted side reaction which ultimately leads to decomposition but with the excess aldehyde 
74 this decomposition does not affect the yield. If, tert-butyl amine were added before 
aldehyde addition, the reactive chloroborane should react to form an aminoborane which may 
be inert towards aldehydes.  
 Once the excess borane is quenched, the aldehyde can be added and the reaction 
should proceed without any decomposition. However, the effect of tert-butyl amine on enol 
borinates, if any, is unknown and would need to be tested. Adding two equivalents of tert-butyl 
amine to the enol borinate of 127 followed by addition of aldehyde resulted in high conversion 
and high diastereoselectivity to the desired aldol adduct 135 (83%, 10:1 dr, Table 2.2, entry 5). 
Lowering the amount of tert-butyl amine resulted in decreased conversion presumably due to 
incomplete quench of the borane reagent. Adding more than two equivalents had no 
noticeable difference in conversion. With a modified aldol procedure developed, the reaction 
could then be applied to an appropriate ketone for the synthesis of linear precursor 4. 
 
 
Scheme 2.11: Selection of an Appropriate Ketone 
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 Of the four synthesized ketones shown in scheme 2.11, ketones 86, 126, and 128 were 
not suitable for the synthesis of precursor 4. Ketone 86 requires harsh conditions for MOM 
ether deprotection which is not suitable for a substrate that is both acid and base sensitive. 
Ketone 126 suffers for a similar reason, as shown; attempts to desulfurize the compound 
resulted in BOM removal as well. Despite this protecting group being removed late stage, 
deprotection at the same stage as desulfurization would result in a 5-hydroxy-7,9-diketone with 
removal of the acetal at C-3 being required. The desired 5-hydroxy-3,7,9-triketone is acid 
sensitive and potentially unstable under ketal removal conditions (requires acid to undergo); 
therefore, ketone 126 was deemed as an inappropriate candidate. Ketone 128 failed to enolize 
efficiently under various conditions (temperature, concentration, reaction time, etc.) so this 
ketone was also abandoned. Ketone 127 on the other hand gave a very promising result, under 
the modified conditions the reaction gave aldol adduct 135 in high yield and high 
diastereoselectivity (83%, 10:1 dr, Table 2.2, entry 5). By simply switching the aldehyde partner 
from 74 to 124 should result in similar conversion and diastereoselectivity to give the carbon 
skeleton of linear precursor 4. As predicted, reaction of 124 with the boron enolate of 127 gave 
136 in similar yield while maintaining high selectivity (80%, dr >15:1).  
 47 
 
 
a) BCy2Cl, Et3N, 
t
BuNH2, DCM b) RANEY® Nickel, EtOH, reflux c) Various Deprotection Conditions 
Scheme 2.12: Aldol Coupling and Synthetic Attempts to Linear Precursor 
 Desulfurization of 136 proceeded smoothly giving the desired carbon skeleton 137 with 
the final steps to reach 4 involving deprotection and redox chemistry. Unfortunately, all 
attempts to remove the acetal in the presence of the silyl ether failed due to the silyl ether 
being more labile than the acetal. At this point, there were three possible solutions. Firstly, 
through a series of protection/deprotection sequences of 138, the desired 139 could be 
synthesized. For instance, protection of the free hydroxyl in 138, removal of the acetal and silyl 
ether, reprotection of the silyl ether at C-5, followed by deprotection of C-9 would give the 
desired 139. This, although possible, would be lengthy and not streamline the synthesis 
towards linear precursor 4. Secondly, by simply switching to a more stable protecting group 
should solve this problem; however as mentioned earlier, various protected ketones of 98 
failed to give high conversion during enolate formation or were unsuitable for late stage 
deprotection. Thirdly, if the sulfur atoms were removed prior to aldol addition, the resulting 
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acylic ketone analogue 140 may allow for different protecting groups to be viable in the 
coupling reaction (Scheme 2.13). 
 Switching to an acyclic ketone raises new synthetic considerations. Previously an (E)-
boron enolate was used to couple 95 and 124 via kinetic resolution with a preferential reaction 
of (3R)-95. Using the same conditions with ketone 140 would be predicted to result in 
preferential reaction of (3R)-141 leading to the undesired aldol adduct. Alternatively, using a 
(Z)-boron or (Z)-titanium enolate should lead to preferential reaction of (3R)-140 and 124 giving 
the desired 6,8-syn-8,9-syn-9,10-Felkin adduct 141 (Scheme 2.13). The pathways leading to 132 
and 141 converge when either compound is subjected to desulfurization and oxidation to give 
diketone 142. The convergence is due to the C-8 (R in 132, S in 141) center becoming 
epimerizable in 142 and likely existing in both keto forms. Finally, a deprotection sequence of 
diketone 142 should provide a route to linear precursor 4.   
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Scheme 2.13: Redesign of Aldol Coupling Partners on the Path to Dolabriferol 
 Focusing on aldol studies of ketone 140, a substantial portion of the methodology has 
recently been developed in the Ward group, where the four diastereomers of the 
tetrapropionate ketone 140 were investigated in aldol coupling reactions.27 In this work, the 
four diastereomers were transformed into the corresponding (Z)-lithium, (Z)-titanium, (Z)-
boron, (E)-lithium, and (E)-boron enolates and reacted with isobutyraldehyde. After workup, 
the distributions of aldol adducts were analyzed, the aldol adducts isolated, and their structures 
determined. This study on the aldol reactions with isobutyraldehyde is the most comprehensive 
to date (four diastereomers, two protecting groups for each, five enolate types for each, forty 
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examples total) and clearly demonstrates that the aldol diastereoselectivities are influenced by 
the relative configuration, protecting group, and enolate type.27  
Table 2.3: Effect of Mediator and Protecting Group on Stereoselectivity  
 
 
Entry PG1 Enolate 
Formation 
Aldol Adducts (Ratio);a Conversiona,b  Yieldc (%) 
1 MOM 9-BBNOTf/Et3N 144ss, 144sa (8.5:1); 95% 77 (9)  
2 MOM LiHMDS then,  
TiCl(Oi-Pr)3 
144ss, 144as (13:1); 90% 76 (5) 
3 TES 9-BBNOTf/Et3N 144ss, 144as (2:1); 70% 38 (17) 
4 TES LiHMDS then,  
TiCl(Oi-Pr)3 
144ss, 144as, 144sa (4:1:0.7); 90% 62 (14) 
a
Determined by 
1
H NMR of the crude reaction mixture. 
b
Estimated from the ratio of adducts to starting ketone 
present in the crude reaction mixture by 
1
H NMR. 
c
Isolated yield of the major adduct (isolated yield of minor 
adduct in parentheses). 
 
 Of particular interest were reactions of the (Z)-boron and (Z)-titanium enolates of 
ketone 140 with isobutyraldehyde (Table 2.3). The major compound in all examples was the 
4,6-syn-6,7-syn diastereomer 143ss with the stereoselectivity ranging from moderate (2:1) to 
high (13:1). Among the various enolates, the titanium enolate prepared from the MOM 
protected 140 by reaction of the lithium (Z)-enolate with TiCl(Oi-Pr)3 gave the highest 
stereoselectivity (Table 2.3, entry 2). With this knowledge, the synthetic plan was to use this 
methodology to couple acyclic ketone 140 with aldehyde 124 under titanium enolate 
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conditions. As discussed earlier, the use of MOM and TES as protecting groups would be 
problematic in the planned deprotection sequence. To overcome this hurdle, it was envisioned 
that replacing MOM with BOM should maintain the high aldol stereoselectivity, allow for 
reductive removal under mild conditions late stage, and would not fall victim to the same fate 
as ketone 126 (acetal removal before desulfurization). Likewise, replacing the TES group with 
TBS should increase the stability of the silyl ether towards acid catalyzed acetal removal 
conditions. To this end, these two ketones were selected as suitable candidates for the 
synthesis of linear precursor 4. 
2.6.2. Acyclic Ketones as Aldol Coupling Partners 
 The synthesis of hydroxy ketone 99 could be achieved simply by desulfurization of the 
thiopyran analogue 98. Although this method works and in moderate yield, the synthesis is not 
economical and requires an additional step, which would only be beneficial if a significant 
improvement in overall yield was achieved. A more direct route to 99 begins with ethyl 
propionate undergoing a Claisen condensation furnishing β-keto-ester 144 (Scheme 2.14).27 
Treatment of 144 with ethylene glycol in the presence of catalytic p-toluenesulfonic acid gave 
the corresponding ketal protected ester. Reduction with LiAlH4 followed by oxidation under 
Swern conditions or with IBX produced aldehyde 145.27 
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 a) 
KO
t
Bu, THF b) ethylene glycol, TsOH, Benzene, reflux c) LiAlH4, THF d) IBX, MeCN, Δ or oxalyl chloride, DMSO, Et3N, 
DCM e) TMS-Cl, NaBr, DMF f) 149, MgBr2•Et2O, DCM g) 149, MgBr2•Et2O, DCM h) RANEY® Nickel, EtOH, reflux i) 
Seperation of Isomers j) RANEY® Nickel, EtOH, reflux k) TBS-Cl, Et3N, DMF l) BOM-Cl, DIPEA, DMF 
 
Scheme 2.14: Various Synthetic Routes to Access Acyclic Ketone 99 
 
 With aldehyde 145 in hand, the next step required the preparation of silyl enol ether 
14927 and subjection to Mukaiyama aldol conditions. Reaction of 145 with 149 mediated by 
MgBr2•OEt2 gave a 1:1 mixture of the desired anti-anti 99 and syn-anti 148 in good yield.
27 The 
desired 99 was obtained by chromatography and protected as its BOM ether 151 (26% over 6 
steps) or its TBS ether 150 (28% over 6 steps) both starting from ethyl propionate. Alternatively, 
Mukaiyama aldol reaction of 149 with aldehyde 74 under Mukaiyama conditions gave a 4:1 
mixture 147aa and 147sa, respectively.32 The higher diastereomeric ratio of the desired aldol 
adduct (4:1 vs 1:1) translated to higher overall yields (BOM ketone 151 (38% over 7 steps) and 
TBS ketone 150 (40% over 7 steps)) compared to the previous route despite requiring an extra 
step to desulfurize. Both routes were scalable, which is an important aspect to consider when 
conducting a multi-step synthesis. Regardless of routes, ketones 150 and 151 were prepared 
 53 
 
and subjected to aldol reaction with 124 via their titanium enolates (Scheme 2.15). As predicted 
from the model study, 124 reacted preferentially with the 4R enantiomer of 150 and 151 
selectively giving the 2,4-syn-1,2-syn-1,8’-syn diastereomers 152 and 153, respectively.  
 
 a) LiHMDS, then TiCl(OiPr)3, then 124, THF b) LiHMDS, then TiCl(OiPr)3, then 124, THF c) RANEY® Nickel, EtOH, 
reflux d) RANEY® Nickel, EtOH, reflux  
 
Scheme 2.15: Aldol Coupling of Acylic Ketones and Proof of Correct Pairing 
 
 Reaction of (±)-150 with 124 resulted in an inseparable 4:1 mixture of diasteromers in 
high yield (84%). The reaction of (±)-151 with 124 was more selective and the diastereomers 
were separable (79% of desired, 7:1 dr). To confirm which enantiomer of (±)-151 had reacted 
with enantioenriched 124 and the structure of 153, the unreacted ketone was recovered ((+)-
151, [α]D=5.2]). If the reaction consumed the desired 4R-enantiomer during coupling, the 
recovered 151 should be enriched in the 4S-enantiomer. Desulfurization by a known method27 
of (-)-98 (90% ee) gave (-)-(4R)-99 (90% ee, [α]D= -6.3). Similarily, deprotection of ketone (+)-151 
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with RANEY® Nickel gave (+)-99 (*α+D= +1.3) that must be enriched in the 4S enantiomer. Two 
important conclusions follow from this result. Firstly, the expected 4R enantiomer of 151 must 
have reacted preferentially during the aldol coupling. Secondly, the magnitude of the recovered 
151, suggests a ca. 20% enantiomeric excess, assuming the rotation is linearly correlated with 
enantiomeric excess. Inserting this value into the equations used in Figure 2.3, gives a 
stereoselectivity factor of 7.5:1 for the kinetic resolution which closely fits the 7:1 ratio of 
diastereomers.  
2.6.3. Deprotection Sequence of TBS Aldol Adduct to Precursor 4 
 The 4:1 mixture of aldol adducts obtained from the reaction of 124 with (±)-150 was 
subjected to iron (III) chloride catalyzed acetal removal to give a separable mixture of 
diastereomers from which dione 154 was isolated in 69% yield (Scheme 2.16). Desulfurization 
of 154 with RANEY® Nickel, followed by oxidation with IBX gave 155, a protected version of the 
target 4. The sequence of deprotection of the TBS ether and benzylidene group could be done 
in either order. Treating compound 155 with TAS-F removed the TBS ether to give 156 which 
existed primarily in two keto forms. Alternatively, hydrogenolysis of 155 with palladium black 
under hydrogen atmosphere removed the benzylidene to furnish hemiacetal 157 
predominately (14:1). To remove the silyl group in 157 required some investigation for 
deprotection methods. The compound is acid sensitive, so conventional acidic deprotection 
methods were out of the question. Using a mild deprotection method, such as HF•pyr/pyr or 
Et3N•3HF resulted in no reaction and spiroketal 158 formation respectively.  
 Compound 158 is interesting, not towards the synthesis of dolabriferol but for structural 
analysis. With this rigid bicyclic system, the two fragments coupled in the aldol reaction of 150 
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and 124 can now be correlated to one another through space using NOE techniques. This is not 
the first synthesis of 158; Lister and Perkins synthesized a very small amount of 158 as a 
byproduct during their synthetic attempts towards dolabriferol.10 Lister and Perkins suggest the 
structure to exist in a chair-chair monoanomeric conformer that places the C-10 methyl group 
in a sterically unfavorable position. Instead, a chair-boat conformer is proposed that allows for 
all substitution to be equatorial and pseudoequatorial in the chair and boat conformers 
respectively (confirmed by J coupling) and makes the spiroketal doubly anomeric. The relative 
configuration of the C-8 center cannot be assigned by J coupling because this position is 
isolated. Using NOE allowed for the assignment of the methyl group at C-8 to be pseudo-
equatorial which Lister and Perkins assigned as axial. Finally, a NOE correlation of the 
hydrogens at C-5 and C-8 strongly supports the chair-boat conformer and is impossible for a 
chair-chair conformer. With the structure of 158 firmly established, the assigned structures for 
155 and 157 are confirmed.  
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a) FeCl3, acetone b) RANEY® Nickel, EtOH, reflux c) IBX, DMSO d) TAS-F, DMF e) Pd, H2, iPrOH f) Pd, H2, iPrOH g) 
TAS-F, DMF h) HF•pyr/pyr, H2O, THF i) Et3N•3HF, Et3N, THF 
 
Scheme 2.16: Final Deprotection Sequence of TBS Route to Linear Precursor 4 
 
 Returning to the deprotection of 157, reaction with TAS-F allowed for mild removal of 
the TBS ether giving linear precursor 4 (10.1% overall, 16 steps from 70) that existed 
predominately as a mixture of two hemiacetal forms (1:0.7) in C6D6 solution (Scheme 2.16). The 
linear precursor 4 can also be obtained by hydrogenolysis of 156 (11.4% overall, 16 steps from 
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70). With this route complete, the focus would now be on synthesis of linear precursor 4 from 
the BOM protected aldol and attempts to synthesize dolabriferol via a retro-Claisen approach.  
2.6.4. Deprotection Sequence of BOM Aldol Adduct to Precursor 4 
 Synthesis of the linear precursor 4 from the BOM aldol adduct 153 began with acetal 
removal with catalytic iron (III) chloride to furnish 159 in high yield (Scheme 2.17). Oxidation of 
the hydroxy group in 159 with IBX gave trione 160 as a mixture of keto and enol tautomers. 
Reaction of 160 with RANEY® nickel resulted in simultaneous desulfurization and BOM 
deprotection to give 156 that existed as a mixture similar in ratio to that observed for 156 
obtained from the the TBS route. Finally, under the known hydrogenolysis conditions, 
compound 156 gave the desired linear precursor 4 in 86% yield (14.3% overall, 15 steps from 
70).  
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a) FeCl3, acetone b) IBX, DMSO c) RANEY® Nickel, EtOH, reflux d) Pd, H2, iPrOH 
 
Scheme 2.17: Final Deprotection Sequence of BOM Route to Linear Precursor 4 
 
With the two routes complete, focus changed to the properties of the putative 
precursor 4 in an effort to better understand the origin of dolabriferol.  
2.7. Dolabriferol – Artifact of Isolation or Enzymatically Controlled? 
2.7.1. Properties of the Linear Precursor 
 As discussed earlier, the linear precursor 4 may exist in a myriad of different ring-chain 
tautomeric forms and as a study of compound 4, the forms it exists in are of particular interest. 
Deprotection of TBS triketone 157 gave a mixture of hemiacetals 167/168 (Figure 2.4) in almost 
equal population (1.4:1). Deprotection of the hydroxy triketone 156 gave the same two 
hemiacetals but in a slightly different ratio (1:1). To better understand the equilibrium of 
tautomers, the mixture was subjected to mild basic conditions (imidazole in CDCl3) to 
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determine if the ratio of hemiacetals would change over time and, if other hemiacetals would 
begin to appear in detectable amounts. After 24 hours, the sample still contained the same two 
hemiacetals 167/168 but the ratio had changed (dr 4:1). From the computational analysis by 
Goodman (Figure 2.4), compounds 161-168 are the lowest energy hemiacetals calculated by 
ROBIA. Hemiacetals 167 (-93.6 KJ/mol) and 168 (-95.7 KJ/mol) are at least 10 KJ/mol lower in 
energy than the next lowest hemiacetal form 162 (-83.9 KJ/mol), this difference in energy 
would approximately equate to a 120:50:1 mixture of 168, 167, and 162 respectively.6 
Thermodynamically, it appears that the C-13-OH to C-9 hemiacetal is the most stable form of 
the linear precursor both by calculation and experimentally. 
 60 
 
 
Figure 2.4: Goodman’s Calculated Energies for Various Hemiacetals of 4 
 In order to form dolabriferol, a retro-Claisen rearrangement must occur from one or 
more of the C-11-OH to C-7 hemiacetals 164-166 and these tautomers are not detected in the 
mixture. Hence, this process may be slow or disfavored relative to unwanted side reactions. 
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2.7.2. Retro-Claisen Attempts on the Linear Precursor 
 With the linear precursor 4 (as a mixture of hemiacetals 167 and 168) in hand, attempts 
at inducing a retro-Claisen rearrangement were initiated. Reaction of 4 with DBU in C6D6 was 
monitored by 1H NMR. Surprisingly, the reaction was sluggish compared to related examples by 
Lister/Perkins,10 Goodman,11 and Ward.14 After five days, the reaction was quenched to 
determine the product distribution. Five distinct products were isolated and characterized: 
dolabriferol 1 (15%), epi-dolabriferol 170 (25%), known lactone 173 (20%)33, cyclic ketone 174 
(10%), and a different mixture of hemiacetals 169 (30%). This result was very intriguing; it 
appeared that the desired retro-Claisen of the C-11-OH to C-7 hemiacetal 164 (not detectable in 
starting material) was occurring faster than retro-Claisen of 167/168 (the only forms visible 
within detection). This desired pathway gives rise to almost half of the recovered material as 
dolabriferol and its epimer 170 so this result was very promising.  
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Scheme 2.18: Subjecting Precursor 4 to DBU and Product Distribution 
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 Products 173 and 174 arise from an unwanted retro-Claisen pathway. The likely 
pathway begins with hemiacetal 161 (C-5-OH to C-9 hemiacetal of 4) undergoing a retro-Claisen 
rearrangement to give TS-171. This “enolate” then undergoes an intramolecular aldol reaction 
to give compound 171. Intramolecular transesterification of 171 (C-13 OH to C-9) would yield 
the two compounds 172 and 173. The appearance of 170 in the reaction mixture suggests that 
the conditions are too basic resulting in epimerization. Consequently, the new hemiacetals 169 
recovered from the reaction may arise from epimerization of 4. Resubjecting 170 to identical 
conditions gave no detectable amount of dolabriferol suggesting epimerization occurs prior to 
retro-Claisen rearrangement.  
 
Table 2.4: Selected 1H NMR Data for Dolabriferol 1 and 170 
 
 
 
4-epi-dolabriferol (170)  dolabriferol (1) 
H Multiplicity  
(J’s in Hz) 
Assignment H Multiplicity  
(J’s in Hz) 
2.74 dq (7.0, 9.0) HC-4 2.78 dq (7.0, 7.0) 
4.24 ddd (3.0, 4.0, 9.0) HC-6 3.75 ddd (5.0, 8.0, 8.0) 
2.63 dq (3.0, 7.0) HC-7 2.73 dq (5.0, 7.0) 
1.87 dq (3.0, 7.0) HC-13 1.91 dq (3.0, 7.0) 
5.25 dd (3.0, 3.0) HC-15 5.25 dd (2.5, 2.5) 
1.76 ddq (3.0, 7.0, 10.5) HC-16 1.78 ddq (2.5, 7.0, 10.0) 
3.63 dd (2.0, 10.5) HC-18 3.61 dd (2.0, 10.5) 
4.03 d (4.5) OH-6 3.63 d (8.0) 
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Table 2.5: Selected 13C NMR Data for Dolabriferol 1 and 170 
 
4-epi-dolabriferol (170)  dolabriferol (1)  
C Assignment C  
47.9 C-4 49.6  
 
13.9 C-5 14.6 
72.5 C-6 75.9 
42.3 C-7 43.9 
10.3 C-8 15.8 
174.9 C-9 173.9 
32.9 C-10 32.7 
 
98.9 C-12 98.7 
39.5 C-13 39.6 
76.4 C-15 77.1 
36.3 C-16 36.7 
72.6 C-18 72.5 
 
 The NMR data for epi-dolabriferol 170 was compared with dolabriferol 1 to possibly 
determine at which position isomerization had occurred. As shown in Tables 2.4 and 2.5, the 
signals for the hemiacetal ring system (C-8 through C-14) in 170 and 1 are almost identical. 
However, signals for the carboxylic acid fragment (C-1 through C-7) of 170 and 1 are very 
different. Due to these differences, it is likely the center that was epimerized is located on the 
acid fragment (C-1 through C-7). Of the positions on this fragment, C-4 and C-6 are the most 
acidic (i.e. prone to epimerization via keto-enol tautomerization) so compound 170 is likely 4-
epi or 6-epi dolabriferol. Conformational analysis (Spartan ’14) suggests that the 4-epi 170 
better matches the data.  
 To reduce the basicity of the retro-Claisen conditions, neutral alumina was selected.34 
Subjecting hemiacetals 167/168 to neutral alumina was very solvent dependent. In refluxing 
ethanol, no reaction was observed even after several hours. However, in benzene at room 
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temperature, the starting material was completely consumed in 72 hours to give a mixture of 
products from which only 175 could be isolated (Table 2.6). Product 175 arises from the correct 
retro-Claisen rearrangement followed by elimination. Controlling the reaction may provide a 
route to the desired dolabriferol 1. Finally, subjecting a benzene solution of hemiacetals 
167/168 to a column of neutral alumina and eluting after 15 minutes gave dolabriferol 1 as the 
only product (75% yield, Table 2.6). A plausible explanation for the difference in reactivity may 
be due to solvent polarity. In ethanol, the compound may be dissolved in the organic phase and 
have very little contact time on the alumina. Changing the solvent to benzene (less polar) and 
applying the sample to neutral alumina allowed for increased contact and therefore a faster 
reaction. The NMR data for synthetic dolabriferol 1 fully matches those reported by Gavagnin4 
(Tables 2.6 and 2.7) and clearly demonstrates that hemiacetals 167/168 can undergo a retro-
Claisen rearrangement to produce dolabriferol under mild conditions. This suggests that 
dolabriferol may indeed be an artifact of isolation and that 4 (along with its tautomers) is a 
plausible natural product.       
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Table 2.6: Comparison of 1H NMR Data for “Natural” and Synthetic Dolabriferol 
 
a) neutral aluminum oxide, benzene, 72 hours b) neutral aluminum oxide, 15 minutes 
 
“natural” dolabriferol  synthetic dolabriferol 
H Multiplicity  
(J’s in Hz) 
Assignment H Multiplicity  
(J’s in Hz) 
1.04 t (7.2) HC-1 1.05 t (7.0) 
2.46 
2.57 
dq (7.2, 14.5)a 
dq (7.2, 14.5)a 
HC-2 
HC-2 
2.46 
2.57 
dq (7.0, 18.0) 
dq (7.0, 18.0) 
2.78 dq (7.1, 7.1) HC-4 2.78 dq (7.0, 7.0) 
1.14 d (7.1) HC-5 1.15 d (7.0) 
3.75 m HC-6 3.75 ddd (5.0, 8.0, 8.0) 
2.73 dq (4.3, 7.1) HC-7 2.73 dq (5.0, 7.0) 
1.32 d (7.1) HC-8 1.33 d (7.0) 
1.60 m HC-10 1.61 m 
0.91 t (7.4) HC-11 0.91 t (7.5) 
1.90 dq (2.5, 7.2) HC-13 1.91 dq (3.0, 7.0) 
0.99b d (7.2) HC-14 1.00 d (7.0) 
5.24 dd (2.5, 2.7) HC-15 5.25 dd (2.5, 2.5) 
1.78 ddq (2.7, 7.0, 10.5) HC-16 1.78 ddq (2.5, 7.0, 10.0) 
0.78 d (7.0) HC-17 0.78 d (7.0) 
3.60 dd (2.0, 10.5) HC-18 3.61 dd (2.0, 10.5) 
1.83 dqq (2.0, 6.8, 6.8) HC-19 1.82 dqq (2.0, 7.0, 7.0) 
1.00b d (6.8) HC-20 0.99 d (7.0) 
0.83 d (6.8) HC-21 0.83 d (7.0) 
3.65  OH-6 3.63 d (8.0) 
3.45  OH-12 3.42 bs 
a
The large coupling constant is misassigned and needs to be corrected
4 b
Incorrect assignment
4  
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Table 2.7: Comparison of 13C NMR Data for “Natural” and Synthetic Dolabriferol 
“natural” 
dolabriferola 
 synthetic 
dolabriferolb 
“natural” 
dolabriferola 
 synthetic 
dolabriferolb 
C Assignment C C Assignment C 
7.4 C-1 7.5 98.5 C-12 98.7 
36.0 C-2 36.2 39.4 C-13 39.6 
215.1 C-3 215.4 20.2 C-14c 13.1 
49.4 C-4 49.6 76.9 C-15 77.1 
14.4 C-5 14.6 36.5 C-16 36.7 
75.7 C-7 75.9 12.9 C-17 13.0 
43.7 C-7 43.9 72.3 C-18 72.5 
15.6 C-8 15.8 28.0 C-19 28.2 
173.7 C-9 173.9 12.9 C-20c 20.5 
32.5 C-10 32.7 14.0 C-21 14.2 
7.2 C-11 7.4    
a
Ref 4; used C CDCl3=77.00 
b
Chemical shifts for synthetic material are consistently 0.1-0.3 ppm higher than those 
reported from the natural product due to a different reference standard; used C CDCl3=77.23 
c
Incorrect 
assignment
4
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2.8. Conclusion 
 In summary, dolabriferol was synthesized via a retro-Claisen rearrangement of its linear 
precursor 4 (existing mainly as hemiacetals 167/168). This work provides the first experimental 
evidence for the retro-Claisen origin of dolabriferol from a contiguous polypropionate (i.e., 1) 
and suggests that dolabriferol is a plausible artifact of isolation. 
 
Scheme 2.19: Overview of the Total Synthesis of Dolabriferol 
 The synthesis of 4 proceeded in a longest linear sequence of 16 steps in 14.3% (via 
ketone 151) or 17 steps in 11.4% (via ketone 150) starting from 70 (23 and 24 total steps 
respectively). The aldol reactions of ketones 150 or 151 with aldehyde 124 proceeded with 
kinetic resolution furnishing the carbon skeleton of 4 with the correct absolute configuration, as 
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predicted. Cheap and achiral precursors were used to prepare the key reactants 150, 151, and 
124. A proline mediated aldol set two of the four stereocenters in aldehyde 124 (C-12 and 13; 
dr >20:1, er 24:1). The remaining stereocenters result from a stereoselective carbonyl reduction 
(C-11; >20:1) and an unprecedented isomerization of a dihydroxy ester (C-10; >20:1). Synthesis 
of racemic ketones 150 and 151 via a Muikayama aldol of 74 and 149 gave the final three 
stereocenters (C-4, 5, 6; dr 4:1) in linear precursor 4. 
 Under mild basic conditions (neutral alumina), the mixture of hemiacetals 167/168 
rapidly equilibrated to hemiacetals 164-166 that underwent retro-Claisen rearrangement to 
give dolabriferol. Thus, dolabriferol is a likely artifact of isolation. Using DBU in CDCl3 to effect a 
retro-Claisen rearrangement (reported by previous groups including the Ward group) was 
sluggish and resulted in a mixture of compounds. The mixture contained dolabriferol (15%), 4-
epi dolabriferol 170 (25%), known lactone 173 (20%), cyclic ketone 174 (10%), and a different 
mixture of hemiacetals 169 (30%), likely from isomerization of C-4. Resubjecting the epimer 170 
to the same conditions resulted in no observable formation of dolabriferol suggesting 
isomerization occurs prior to the rearrangement.  
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2.9. Suggestions for Future Work 
 On the basis that dolabriferol is likely an artifact of isolation, similar non-contiguous 
polypropionate ester natural products may also be derived from a linear precursor undergoing 
rearrangement. These compounds are therefore potential targets to test this hypothesis. In 
2012, Jiménez-Romero et al isolated two new polypropionates along with dolabriferol from 
Dolabrifera dolabrifera off the coast of Puerto Rico.35 Of particular interest is dolabriferol B 
which is not only a non-contiguous polypropionate; it also has an identical stereochemical array 
as dolabriferol.  
 
Scheme 2.20: Proposed Retrosynthetic Approach to Dolabriferol B 
 Adapting a similar retrosynthetic design as the one used for dolabriferol (where 
synthesis of the linear precursor 4 was the goal) gives the linear precursor 176. Starting with 
176, the retrosynthetic design is almost identical where the only difference being 177 being a 
des-methyl analogue of 124. This would be accomplished by coupling propanal instead of 
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isobutyraldehyde with 75 in the proline catalyzed aldol. From there, the synthesis would follow 
identical steps. Alternatively, diketone 178 can be used as the ketone coupling partner to 
aldehyde 177. Current research in the Ward group has shown promising results of a 1,5-
diketone underoing bisenolate formation. The control over which ketone reacts has been 
shown in several examples to give the corresponding mono-aldol.28 With further development 
of this methodology and the synthesis of aldehyde fragments 177, application of this new 
methodology should allow access to precursor 176 and, ultimately, to dolabriferol B.   
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3. EXPERIMENTAL 
3.1. General Methods 
 Anhydrous solvents were distilled under argon atmosphere as follows.  Tetrahydrofuran 
(THF) from benzophenone sodium ketyl; CH2Cl2 from CaH2; MeOH from Mg(OMe)2. All 
experiments involving air- and/or moisture-sensitive compounds were conducted in an oven 
dried round-bottom flask capped with a rubber septum and attached via a needle and 
connecting tubing to a mercury bubbler under argon atmosphere.  Low temperature baths 
were: ice/water (0 °C), CO2(s)/acetonitrile (-45 °C), and CO2(s)/acetone (-78 °C). Unless 
otherwise noted, reaction temperatures refer to that of the bath.  
 Palladium hydrogenations were conducted at room temperature in a vial which was 
placed in a Parr hydrogenation apparatus. The atmosphere was purged with argon and then 
filled with hydrogen (H2, 50-60 psi). After the reactions were completed, the catalyst was 
removed by filtration through Celite, followed by thorough washing of the filter cake with 
MeOH.  RANEY® nickel desulfurizations were conducted in refluxing ethanol in a round bottom 
flasked equipped with a reflux condenser and a balloon filled with hydrogen (H2) attached via a 
needle.  
 Preparative TLC was carried out on glass plates (20x20 cm) pre-coated (0.25 mm) with 
silica gel 60 F254.  Materials were detected by visualization under an ultraviolet lamp (254 nm) 
and/or by treating a 1 cm vertical strip removed from the plate with a solution of 
phosphomolybdic acid (5%) containing a trace of ceric sulfate in aq. sulfuric acid (5% v/v), or 
with basic KMnO4 [KMnO4 (1.5 g), K2CO3 (10 g), 10% aq. NaOH (1.25 mL), in H2O (200 mL)], 
 73 
 
followed by charring on a hot plate. TLC was carried out on glass plates (1x3 cm) pre-coated 
(0.25 mm) with silica gel 60 F254 and was visualized in the same manner as described for PTLC.  
 Flash column chromatography (FCC) was performed according to Still et al.36 with Merck 
silica gel 60 (40-63 mm).  All mixed solvents eluents are reported as v/v solutions. Unless 
otherwise noted, all reported compounds were homogenous by thin layer chromatography 
(TLC) and by 1H NMR spectroscopy.  
 Concentration refers to removal of volatiles with a rotary evaporator under vacuum 
supplied by a water aspirator. Evacuation at ca. 0.5 torr with a vacuum pump generally followed 
rotary evaporation. 
3.2. Spectral Data 
 High resolution mass spectra (HRMS) and low resolution mass spectra (LRMS) were 
obtained on a VG 70E double focussing high resolution spectrometer; only partial data are 
reported. Electron impact (EI) ionization was accomplished at 70 eV, chemical ionization (CI) at 
50 eV with ammonia as the reagent gas. Alternatively, HRMS was obtained on a LC-MS/MS 
time-of-flight high resolution spectrometer with electrospray ionization (ESI) from acetonitrile 
solution.   
 Infrared spectra were recorded on a Fourier transform interferometer using a diffuse 
reflectance cell (DRIFT); only diagnostic peaks and/or intense peaks are reported. Unless 
otherwise noted, all experiments used DRIFT. 
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 Unless otherwise noted, NMR spectra were measured in CDCl3 solution at 500 MHz for 
1H and 125 MHz for 13C. Signals due to the solvent (13C NMR) or residual protonated solvent (1H 
NMR) served as the internal standard: CDCl3 (7.26 H, 77.23 C); C6D6 (7.16 H, 128.39 C). The 
1H NMR chemical shifts and coupling constants were determined assuming first-order behavior. 
Multiplicity is indicated by one or more of the following: s (singlet), d (doublet), t (triplet), q 
(quartet), m (multiplet), br (broad), ap (apparent); the list of couplings constants (J) 
corresponds to the order of the multiplicity assignment. Coupling constants are reported to the 
nearest 0.5 Hz (digital resolution ca, 0.1 Hz/pt) or the nearest 0.1 Hz (digital resolution ca. 0.03 
Hz/pt.). The 1H NMR assignments were made on the basis of chemical shift and multiplicity and 
were confirmed, where necessary, by homonuclear decoupling and/or two-dimensional 
correlation experiments (gCOSY, gHSQC, gHMBC).37 The 13C NMR assignments were made on 
the basis of chemical shift and multiplicity (as determined by 13C-DEPT or gHSQC) and were 
confirmed, where necessary, by two-dimensional 1H/13C correlation experiments (gHSQC 
and/or gHMBC).37 The multiplicity of 13C NMR signals refers to the number of attached 
hydrogens (ie., s = C, d = CH, t = CH2, q = CH3). 
 Specific rotations (*α+D) are the average of five determinations at ambient temperature 
using 1 mL, 10 dm cell; the units are 10-1 deg cm2 g-1 and the concentrations (c) are reported in 
g/100 mL. The values reported are rounded to reflect the accuracy of the measured 
concentrations (the major source of error). HPLC analyses were carried out using am Agilent 
Technologies 1200 series liquid chromatograph. 
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3.3. Materials 
 The following compounds and reagents were prepared as described previously: 71,17 
72,17 73,17 74,27 75,18 84,17 86,20 98,19 99,26 125,19 127,20 144,26 145,26 148,26 149,26 IBX,38 W-2 
RANEY® Nickel,39 methyl cyanoformate,40 and benzyl cyanoformate.41 Et3N and DIPEA were 
distilled from KOH under argon and were stored over KOH. n-Butyl lithium and t-butyl lithium 
were titrated using diphenylacetic acid as the titrant and indicator. TiCl4 and HMDS were 
distilled under argon atmosphere from CaH2. All other reagents were commercially available 
and, unless otherwise noted, were used as received. 
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3.4. Experimental Procedures and Spectral Data for Compounds 
Dolabriferol (1).  
 
1 
 Linear precursor 4 (2 mg, 5.2 micromol) was dissolved in benzene (0.2 mL) and 
transferred to a pipette containing neutral alumina (3 cm height, Brockmann I) and the solvent 
pushed down until the solvent line was below the alumina line. After 15 minutes, the column 
was eluted with EtOAc (3x) and the solvent evaporated under reduced pressure to give the title 
compound (1.5 mg, 75%, >95% purity by 1H NMR analysis). 
colorless oil, TLC Rf = 0.3 (40% ethyl acetate in hexane);  
1H NMR (CDCl3) : 5.25 (1H, dd, J = 2.5, 2.5 Hz, HC-15), 3.75 (1H, ddd, J = 5, 8, 8 Hz, HC-6), 3.63 
(1H, d, J = 8 Hz, HOC-6), 3.61 (1H, dd, J = 2, 10.5 Hz, HC-18), 3.42 (1H, bs, HOC-12), 2.78 (1H, dq, 
J = 7, 7 Hz, HC-4), 2.73 (1H, dq, J = 5, 7 Hz, HC-7), 2.57 (1H, dq, J = 18, 7 Hz, HC-2), 2.46 (1H, dq, J 
= 18, 7 Hz, HC-2), 1.91 (1H, dq, J = 3, 7 Hz, HC-13), 1.82 (1H, dqq, J = 2, 7, 7 Hz, HC-19), 1.78 (1H, 
ddq, J = 2.5, 10, 7 Hz, HC-16), 1.68-1.50 (2H, m, H2C-10), 1.33 (3H, d, J = 7 Hz, HC-8), 1.15 (3H, d, 
J = 7 Hz, H3C-5), 1.05 (3H, t, J = 7 Hz, H3C-1), 1.00 (3H, d, J = 7 Hz, H3C-14), 0.99 (3H, d, J = 7 Hz, 
H3C-20), 0.91 (3H, t, J = 7.5 Hz, H3C-11), 0.83 (3H, d, J = 7 Hz, H3C-21), 0.78 (3H, d, J = 7 Hz, H3C-
17);  
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13C NMR (CDCl3) : 215.4 (s, C-3), 173.9 (s, C-9), 98.7 (s, C-12), 77.1 (d, C-15), 75.9 (d, C-6), 72.5 
(d, C-18), 49.6 (d, C-4), 43.9 (d, C-7), 39.6 (d, C-13), 36.7 (d, C-16), 36.2 (t, C-2), 32.7 (t, C-10), 
28.2 (d, C-19), 20.5 (q, C-20), 15.8 (q, C-8), 14.6 (q, C-5), 14.2 (q, C-21), 13.1 (q, C-14), 13.0 (q, C-
17), 7.5 (q, C-1), 7.4 (q, C-11); 
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(4S,5R,6R,10S,11S,12S,13S)-5,11,13-Trihydroxy-4,6,8,10,12,14-hexamethylpentadecane-3,7,9-
trione (4).  
 
4 
 From TBS-diol. Tris(dimethylamino)sulfonium difluorotrimethylsilicate (TAS-F; 24 mg, 
0.087 mmol) was added to a stirring solution of 157 (10 mg, 0.020 mol) in DMF (0.3 mL) at 
room temperature under argon. After 3 h, the mixture was diluted with ethyl acetate and 
washed sequentially by saturated aq NaHCO3, water, and brine, dried over Na2SO4, 
concentrated and fractionated by FCC (30%-50% ethyl acetate in hexane) to give the title 
compound (6 mg, 78%) that was predominantly a 3:2 mixture of two hemiacetal forms (HOC-13 
 O=C-9; presumably epimeric at C-8) in C6D6 solution.  
 From Benzylidene. Freshly prepared palladium black (98 mg, 0.92 mmol) was added to a 
stirred solution of 156 (20 mg, 0.042 mmol) in i-PrOH (5mL) at ambient temperature under Ar. 
The reaction vessel was evacuated and placed under a H2 atmosphere (60 psi). After stirring for 
16 h, the supernatant was removed and the Pd was washed with MeOH (×2). The organic layers 
were filtered through Celite® and the combined filtrate was concentrated and fractionated by 
FCC (30-50% ethyl acetate in hexane) to give the title compound (14 mg, 86%) that was 
predominantly a 1:1 mixture of two hemiacetal forms (HOC-13  O=C-9; presumably epimeric 
at C-8) in C6D6 solution.  
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colorless oil, TLC Rf = 0.3 (50% ethyl acetate in hexane);  
*α+D –30 (c 0.5, C6H6);  
IR max: 3414, 1699 cm
-1
;  
1H NMR (C6D6)  (* denotes signals for the minor hemiacetal): 5.50 (0.6H, s, HOC-9), 5.00 (0.4H, 
s, HOC-9*), 3.84-3.68 (2H, m, HC-5, HC-5*, HOC-11, HOC-11*), 3.65 (0.4H, dd, J = 2, 11 Hz, HC-
13*), 3.58 (0.6H, dd, J = 2, 11 Hz, HC-13), 3.36 (0.6H, dq, J = 7, 7 Hz, HC-6), 3.13 (0.4H, ddd, J = 
2.5, 2.5, 7 Hz, HC-11*), 3.11-2.99 (2.4H, m, HC-6,* HC-8, HC-8*, HC-11, HC-11*), 2.53 (0.4H, dq, 
J = 4.5, 7 Hz, HC-4*), 2.51 (0.6H, dq, J = 4.5, 7 Hz, HC-4), 2.23 (0.4H, dq, J = 18.5, 7 Hz, HC-2*), 
2.21 (0.4H, d, J = 7.5 Hz, HOC-11*), 2.17-2.03 (2.2H, m, HC-2*, H2C-2, HOC-11 ), 1.74-1.62 (1H, 
m, HC-14, HC-14*), 1.51 (0.4H, dq, J = 2.5, 7 Hz, HC-10*), 1.35 (0.6H, dq, J = 2.5, 7 Hz, HC-10), 
1.31 (0.4H, ddq, J = 2.5, 11, 7 Hz, HC-12*), 1.24 (1.2H, d, J = 7 Hz, H3CC-8*), 1.21 (0.6H, ddq, J = 
2.5, 11, 7 Hz, HC-12), 1.15 (1.2H, d, J = 7 Hz, H3CC-10*), 1.14 (1.8H, d, J = 7 Hz, H3CC-8*), 1.103 
(1.8H, d, J = 7 Hz, H3CC-6 or H5CC-15), 1.102 (1.8H, d, J = 7 Hz, H3CC-6 or H5CC-15), 1.06 (1.2H, 
d, J = 7 Hz, H3CC-15*), 1.02 (1.2H, d, J = 7 Hz, H3CC-4*), 1.00 (1.2H, d, J = 7 Hz, H3CC-6*), 0.97 
(1.2H, t, J = 7 Hz, H3C-1*), 0.96 (1.8H, d, J = 7 Hz, H3CC-4), 0.95 (1.8H, d, J = 7 Hz, H3CC-10), 0.93 
(1.8H, t, J = 7 Hz, H3C-1), 0.87 (1.8H, d, J = 7 Hz, H3C-15), 0.85 (1.2H, d, J = 7 Hz, H3C-15*), 0.71 
(1.2H, d, J = 7 Hz, H3CC-12*), 0.65 (1.8H, d, J = 7 Hz, H3CC-12);  
13C NMR (C6D6)  (* denotes signals for the minor hemiacetal): 218.5* (s, C-7), 217.4 (s, C-7), 
215.4 (s, C-3), 215.0* (s, C-3), 102.4 (s, C-9), 101.8* (s, C-9), 78.8 (d, C-5), 78.0* (d, C-5), 77.2* 
(d, C-11), 76.7 (d, C-11), 72.7* (d, C-13), 72.6 (d, C-13), 54.5* (d, C-8), 54.2 (d, C-8), 49.6 (d, C-6), 
49.2* (d, C-6), 48.33* (d, C-4), 48.31 (d, C-4), 41.5* (d, C-10), 39.1 (d, C-10), 38.2* (d, C-12), 37.9 
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(d, C-12), 36.5 (t, C-2), 35.9* (t, C-2), 28.9 (d, C-14), 28.7* (d, C-14), 21.1 (q, C-15), 20.9* (q, C-
15), 15.32* (q, H3CC-6), 15.25 (q, H3CC-6), 15.13 (q, H3CC-4), 15.08* (q, H3CC-4), 14.9* (q, H3CC-
15), 14.84 (q, H3CC-15), 14.76* (q, H3CC-10), 13.92 (q, H3CC-12), 13.85* (q, H3CC-12), 13.6 (q, 
H3C-C10), 12.5 (q, H3CC-8), 11.8* (q, H3CC-8), 7.94* (q, C-1), 7.92 (q, C-1);  
HRMS m/z calcd. for C21H38O6+Na 409.2561, found 409.2564 (ESI). 
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(S)-3-((S)-1-Hydroxy-2-methylpropyl)dihydro-2H-thiopyran-4(3H)-one (97) 
 
97 
 L-Proline (5.1 g, 44 mmol) was added in one portion to a stirred solution of 75 (10.0 g, 
86.2 mmol) and isobutyraldehyde (23.6 mL, 18.6 g, 258 mmol) in DMSO (30 mL). After 4 days, 
the mixture was diluted with ethyl acetate and washed sequentially with saturated NH4Cl, 
water and brine, dried over Na2SO4, concentrated, and fractionated by FCC (20% ethyl acetate 
in hexane) to furnish the title compound (12.5 g, 77%; er 24:1 by HPLC). 1H NMR data were 
consistent with those previously reported.26 
colorless oil; TLC Rf = 0.30 (20% ethyl acetate in hexane); 
[α]D  –22 (c 2.2, CHCl3) (lit.
26 *α+D –23; c 1.0, CHCl3; 98% ee) 
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(4R,5S,6S)-rel-6-(2-Ethyl-1,3-dioxolan-2-yl)-5-hydroxy-4-methylheptan-3-one (99). 
 
99 
 A suspension of Raney nickel (W2; 10 mL settled volume) in EtOH (20 mL) was added to 
147aa (2.83 g, 10.3 mmol) and the mixture was heated under reflux with vigorous stirring. After 
5 h (reaction was complete by TLC analysis), the mixture was decanted and the solid was 
suspended in EtOH (3 mL) and heated under reflux with vigorous stirring for several min. This 
washing procedure was repeated with acetone (×2) and methanol. The combined organic layers 
were filtered through Celite®, concentrated, and fractionated by FCC (25% Et2O in hexane) to 
give the title compound as a colorless oil (2.21 g, 88%); NMR data were consistent with those 
reported previously.27 
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(S)-3-((S)-2-Methyl-1-((triethylsilyl)oxy)propyl)dihydro-2H-thiopyran-4(3H)-one (107). 
 
 
107 
 Et3N (10.5 mL, 7.62 g, 75.5 mmol) and Et3SiCl (9.6 mL, 8.6 g, 57 mmol) were sequentially 
added to a stirred solution of 97 (7.16 g, 38.1 mmol) in CH2Cl2 (50 mL) room temperature under 
Ar. After 16 h, the reaction was diluted with CH2Cl2, washed with saturated aq NH4Cl and brine, 
dried over Na2SO4, and concentrated to give the crude product as a dark brown oil. The crude 
product was fractionated by FCC (0-10% ethyl acetate in hexane) to furnish the title compound 
as a pale yellow oil (10.82 g, 94%). 
colorless liquid, TLC Rf = 0.30 (5% ethyl acetate in hexane); [α]D –99 (c 5.2, CHCl3); 
IR (DRIFT) max 1712 cm
-1
. 
1
H NMR (500 MHz, CDCl3)  4.20 (1H, dd, J = 4, 6 Hz, HC-1'), 2.98-2.88 (3H, m, HC-2, H2C-6), 
2.83-2.73 (3H, m, HC-2, HC-3, HC-5), 2.66 (1H, ap ddd, J = 5.5, 8.5, 14 Hz, HC-5), 1.71 (1H, dqq, J 
= 4, 6.5, 6.5 Hz, HC-2'), 0.93 (9H, t, J = 8 Hz, H3CCSi ×3), 0.89 (3H, d, J = 6.5 Hz, H3C-3'), 0.87 (3H, 
d, J = 6.5 Hz, H3C-3'), 0.59 (6H, ap q, J = 8 Hz, H2CSi ×3). 
13
C NMR (125 MHz, CDCl3)  209.1 (s, C-4), 74.9 (d, C-1'), 58.7 (d, C-3), 44.0 (t, C-5), 31.6 (t, C-2), 
30.9 (d, C-2'), 30.5 (t, C-6), 20.6 (q, C-3'), 17.0 (q, C-3'), 7.2 (q ×3, CH3CSi), 5.5 (t ×3, CH2Si). 
HRMS m/z calcd. for C15H30O2SiS 302.1736, found 302.1730 (EI). 
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Methyl (5S)-5-((S)-2-Methyl-1-(hydroxy)propyl)-4-oxotetrahydro-2H-thiopyran-3-carboxylate 
(109). 
 
109 
 t-BuLi (1.5 M in hexanes; 31 mL, 47 mmol) was added dropwise to a stirred solution of 
107 (10.31 g, 34.1 mmol) and 1,10-phenanthroline (100 mg, 0.55 mmol) in THF (200 mL) at –78 
°C under Ar until a deep purple colored persisted. After 10 min, CH3O2CCN (5.7 mL, 6.1 g, 72 
mmol) was added. After 10 min, the mixture became bright yellow and the reaction was 
quenched by addition of saturated aq NH4Cl. The mixture was extracted with ethyl acetate and 
the combined organic layers were dried over Na2SO4 and concentrated to give a yellow oil that 
was taken up in CH3CN (120 mL) and aq HF (5 wt. %; 30 mL) was added to the stirred solution. 
After 2 h, the mixture was diluted with ethyl acetate, washed with NaHCO3 and brine, dried 
over Na2SO4, concentrated, and fractionated by FCC (20% ethyl acetate in hexane) to give the 
title compound as a 2:3:3 mixture of enol and two keto tautomers, respectively (7.53 g, 91%). 
pale yellow oil, TLC Rf = 0.3 (20% ethyl acetate in hexane);  
IR max: 3544, 1744, 1697, 1645, 1608 cm
-1
;  
1H NMR (CDCl3)  (*denotes signals from enol form): 12.99* (0.19H, s, HO enol), 3.85-3.71 
(0.66H, m, HC-1', 2× keto), 3.80 (s), 3.78 (s) and 3.77 (s) (3H, H3CO enol & 2× keto), 3.67-3.63 
(0.22H, m, HC-1' enol), 3.51-3.40 (1H, m, enol & 2× keto), 3.37-3.23 (1H, m, enol & 2× keto), 
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3.18-2.82 (3.77H, m), 2.80-2.62 (0.88H, m), 2.57 (0.36H, d, J = 8 Hz, HO keto), 1.99 (0.23H, dqq, J 
= 5, 7, 7 Hz, HC-2' enol), 191 (0.38H, dqq, J = 6, 7, 7 Hz, HC-2' keto), 1.82 (0.39H, dqq, J = 5, 7, 7 
Hz, HC-2' keto), 1.05-0.92 (6.2H, m, H3C-3' (×2) enol & 2× keto);  
13C NMR (CDCl3)  (*denotes signals from enol form): 208.2 (s), 207.7 (s), 173.5* (s), 172.4* (s), 
169.1 (s), 169.0 (s), 98.7* (s), 80.1* (d), 78.0 (d), 76.2 (d), 60.8 (d), 58.6 (d), 56.9 (d), 54.3 (d), 
52.9 (q), 52.6 (q), 52.2* (q), 42.2* (d), 34.5 (t), 34.4 (t), 33.5 (t), 33.2 (t), 31.4* (d), 31.3 (d), 30.3 
(d), 29.3* (t), 23.6* (t), 20.3 (q), 19.9* (q), 19.8 (q), 17.6 (q), 17.1* (q), 16.5 (q);  
HRMS m/z calcd. for C11H18O4S 246.0926, found 246.0926 (EI). 
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Methyl (3R,4S,5S)-4-Hydroxy-5-((S)-1-hydroxy-2-methylpropyl)tetrahydro-2H-thiopyran-3-
carboxylate (111).  
 
111 
 See the preparation of 112 
white amorphous solid; TLC Rf = 0.30 (45% ethyl acetate in hexane)  
*α+D –48 (c 1.3, CHCl3);  
IR max: 3448, 1712 cm
-1
;  
1H NMR (CDCl3) : 4.19 (1H, br s, HC-4), 3.76 (3H, s, H3CO), 3.69 (1H, dd, J = 3.5, 8 Hz, HC-1'), 
3.66 (1H, br s, HO), 3.19-3.13 (2H, m, HC-2, HC-3), 2.96 (1H, dd, J = 3.5, 14 Hz, HC-6), 2.79 (1H, 
br s, HO), 2.63 (1H, dd, HC-2), 2.29 (1H, dd, J = 7, 14 Hz, HC-6), 2.12 (1H, dddd, J = 3.5, 7, 7, 8 Hz, 
HC-5), 1.86 (1H, dqq, J = 3.5, 7, 7 Hz, HC-2'), 1.00 (3H, d, J = 7 Hz, H3C-3'), 0.89 (3H, d, J = 7 Hz, 
H3C-3');  
13C NMR (CDCl3) : 174.4 (s, CO), 77.8 (d, C-1'), 69.9 (d, C-4), 52.4 (q, CH3O), 45.3 (d, C-3), 42.8 
(d, C-5), 30.2 (d, C-2'), 27.5 (t, C-6), 26.7 (t, C-2), 20.2 (q, C-3'), 15.1 (q, C-3');  
HRMS m/z calcd. for C11H20O4S: 248.1082; found: 248.1090 (EI). 
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Methyl (3S,4S,5S)-4-Hydroxy-5-((S)-1-hydroxy-2-methylpropyl)tetrahydro-2H-thiopyran-3-
carboxylate (112).  
 
112 
 From 109: Et2BOMe (1.4 mL, 1.1 g, 11 mmol) was added to a stirred solution of 109 
(1.86 g, 7.69 mmol) in THF (100 mL) at room temperature under argon. After 30 min, the 
mixture was cooled to –78 °C and MeOH (25 mL) was added. After 15 minutes, solid NaBH4 (803 
mg, 21.2 mmol) was added. After 1 h, the reaction vessel was removed from the bath and the 
mixture allowed to warm with stirring. After 30 min, the mixture was cooled to 0 °C and the 
reaction was quenched by sequential addition of phosphate buffer (pH = 6.8; 1 M, 50 mL) and 
30% aq H2O2 (6.8 mL, 60 mmol). After 15 min, the mixture was diluted with water and extracted 
with ethyl acetate. The combined organic layers were washed sequentially with saturated 
Na2SO3, water and brine, dried over Na2SO4, and concentrated to give the crude product whose 
1H NMR spectrum indicated the presence of a 1.3:1 mixture of diastereomeric diols. 
Fractionation of the crude product by FCC (40% ethyl acetate in hexane) gave the 
trans_syn_diol (710 mg, 38%) the title compound (830 mg, 45%).  
 From isomerization of 111 (this procedure was developed by Naveen Diddi). Freshly 
sublimed KOtBu (657 mg, 5.83 mmol) was added to a stirred solution 111 (710 mg, 2.91 mmol) 
and CuI (55 mg, 0.29 mmol) in dry Et2O (60 mL) at 0 °C under argon. After 5 min, the reaction 
was quenched by addition of saturated aq NH4Cl. The mixture was diluted with Et2O and the 
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combined organic layers were washed sequentially with saturated aq NaHCO3 and brine, dried 
over Na2SO4, concentrated, and the residue fractionated by FCC (40% ethyl acetate in hexane) 
to afford the title compound (517 mg, 73%). 
white amorphous solid; TLC Rf = 0.30 (40% ethyl acetate in hexane) 
*α+D +30 (c 1.0, CHCl3);  
IR max: 3360, 3193, 1728 cm
-1
;  
1H NMR (C6D6) : 3.67 (1H, dd, J = 9.5, 9.5 Hz, HC-4), 3.28 (3H, s, H3CO), 3.06 (1H, dd, J = 3, 7.5 
Hz, HC-1'), 2.78 (1H, ddd, J = 4, 10, 11.5 Hz, HC-3), 2.51 (1H, dd, J = 11.5, 13.5 Hz, HC-2), 2.45 
(1H, ddd, J = 2.5, 4, 13.5 Hz, HC-2), 2.10 (1H, ddd, HC-6), 1.87-1.77 (2H, m, HC-5, HC-6), 1.41 
(1H, dqq, J = 3, 7, 7 Hz, HC-2'), 0.86 (3H, d, J = 7 Hz, H3C-3'), 0.75 (3H, d, J = 7 Hz, H3C-3');  
13C NMR (C6D6) : 174.1 (s, CO), 80.7 (d, C-1'), 76.3 (d, C-4), 53.2 (d, C-3), 51.9 (d, CH3O), 47.5 (d, 
C-5), 30.5 (d, C-2'), 30.2 (t, C-2), 29.9 (t, C-6), 20.4 (q, C-3'), 14.7 (q, C-3');  
HRMS m/z calcd. for C11H20O4S: 248.1082; found: 248.1079 (EI). 
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Methyl (2S,4S,4aS,8S,8aS)-4-Isopropyl-2-phenylhexahydrothiopyrano[4,3-d][1,3]dioxine-8-
carboxylate (112a).  
 
112a 
 PhCH(OCH3)2 (2.1 mL, 2.1 g, 14 mmol) and p-TsOH·H2O (118 mg, 0.62 mmol) were 
sequentially added to a stirred solution of 112a (651 mg, 2.67 mmol) in CH2Cl2 (30 mL) at 
ambient temperature. After 16 h, the reaction was diluted with CH2Cl2, washed sequentially 
with saturated aq NaHCO3 and brine, dried over Na2SO4, and concentrated to afford a pale 
yellow oil containing the title compound and PhCH(OCH3)2. The oil was dissolved in refluxing 
hexane (~50 mL) and, after cooling to ambient temperature, the solution was left in a freezer (-
20°C) overnight to induce crystallization. The white solid was collected by filtration and the 
combined filtrate and washings were concentrated to give an oil that was subjected to a second 
round of crystallization. The combined solids were dried under high vacuum to afford the title 
compound (815 mg, 89%).  
white crystalline solid, mp 171-173°C, TLC Rf = 0.3 (20% ethyl acetate in hexane);  
*α+D +30 (c 0.6, CHCl3);  
IR max: 1732 cm
-1
;  
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1H NMR (C6D6) : 7.58 (2H, ap d, J = 7.5 Hz, Ph), 7.17-7.13 (2H, m, Ph), 7.09 (1H, ap t, J = 7.5 Hz, 
Ph), 5.43 (1H, s, HC-2), 3.63 (1H, dd, J = 10, 10 Hz, HC-8a), 3.28 (3H, s, H3CO), 3.02 (1H, ddd, J = 
3.5, 10, 12 Hz, HC-8), 2.94 (1H, dd, J = 2, 9.5 Hz, HC-4), 2.82 (1H, dd, J = 12, 13.5 Hz, HC-7), 2.37 
(1H, ddd, J = 1.5, 3.5, 13.5 Hz, HC-7), 2.05-1.95 (2H, m, HC-4a, HC-5), 1.82 (1H, dd, J = 12.5, 13.5 
Hz, HC-5), 1.44 (1H, ddq, J = 2, 7, 7 Hz, HC-1'), 0.97 (3H, d, J = 7 Hz, H3C-2'), 0.81 (3H, d, J = 7 Hz, 
H3C-2');  
13C NMR (C6D6) : 172.8 (s, C=O), 139.3 (s, Ph), 128.8 (d, Ph), 128.4 (d ×2, Ph), 126.5 (d ×2, Ph), 
101.1 (d, C-2), 83.5 (d, C-4), 81.2 (d, C-8a), 51.4 (q, CH3O), 50.3 (d, C-8), 43.2 (d, C-4a), 30.2 (t, C-
7), 28.2 (d, C-1'), 27.2 (t, C-5), 20.0 (q, C-2'), 14.8 (q, C-2');  
HRMS m/z calcd. for C18H24O4S 336.1395, found 336.1400 (EI).  
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((2S,4S,4aS,8R,8aR)-4-Isopropyl-2-phenylhexahydrothiopyrano[4,3-d][1,3]dioxin-8-
yl)methanol (123). 
 
123 
 LiAlH4 (92 mg, 2.4 mmol) was added in one portion to a stirred solution of 112a (815 mg, 
2.43 mmol) in THF (20 mL) at 0 °C under argon. After 15 min, the ice bath was removed and 
stirring continued until the reaction was complete by TLC analysis (ca. two hours). The reaction 
was quenched by sequential addition of water (0.1 mL), 15% aq NaOH (0.1 mL), and water (0.3 
mL) with vigorous stirring. After the hydrogen evolution had subsided, the mixture was 
concentrated and the resulting residue was suspended in Et2O (50 mL)with vigorous stirring. 
The initially grey suspension became a fine white powder (ca. 1 h). The mixture was filtered 
through a column of Celite® and the combined filtrate and ethyl acetate washings were 
concentrated to give a white solid. The solid was fractionated by FCC (20% ethyl acetate in 
hexane) to give the title compound as a white solid (728 mg, 97%).  
white crystalline solid, mp 183-184°C, TLC Rf = 0.3 (40% ethyl acetate in hexane);  
*α+D –8.7 (c 1.2, CHCl3);  
IR max: 3344 cm
-1
;  
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1H NMR (CDCl3) : 7.45-7.28 (5H, m, Ph), 5.61 (1H, s, HC-2), 3.83 (1H, dd, J = 6, 11 Hz, H2CO), 
3.64 (1H, dd, J = 4.5, 11 Hz, H2CO), 3.50 (1H, dd, J = 10, 10 Hz, HC-8a), 3.42 (1H, dd, J = 2, 10 Hz, 
HC-4), 2.65-2.55 (2H, m, H2C-7), 2.50 (1H, br d, J = 13.5 Hz, HC-5), 2.34 (1H, dd, J = 12, 13.5 Hz, 
HC-5), 2.25-2.15 (2H, m, HC-8, HO), 2.11 (1H, dddd, J = 3.5, 10 ,10, 12 Hz, HC-4a), 1.93 (1H, dqq, 
J = 2, 7, 7 Hz, HC-1'), 1.08 (3H, d, J = 7 Hz, H3C-2'), 0.98 (3H, d, J = 7 Hz, H3C-2');  
13C NMR (CDCl3) : 138.6 (s, Ph), 129.0 (d, Ph), 128.4 (d ×2, Ph), 126.1 (d ×2, Ph), 100.9 (d, C-2), 
84.2 (d, C-8a), 84.0 (d, C-4), 65.9 (t, CH2O), 45.6 (d, C-8), 43.4 (d, C-4a), 29.7 (t, C-7), 28.5 (d, C-
1'), 27.7 (t, C-5), 20.2 (q, C-2'), 15.1 (q, C-2');  
HRMS m/z calcd. for C17H24O3S 308.1446, found 308.1442 (EI). 
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(2S,4S,4aS,8S,8aS)-4-Isopropyl-2-phenylhexahydrothiopyrano[4,3-d][1,3]dioxine-8-
carbaldehyde (124). 
 
124 
 Oxalyl chloride (0.32 mL, 0.48 g, 3.7 mmol) was added over 5 min to a stirred solution of 
DMSO (0.27 mL, 0.30 g, 3.8 mmol) in CH2Cl2 (60 mL) at –78 °C under argon. After 20 min, a 
solution of 123 (728 mg, 2.36 mmol) in CH2Cl2 (20 mL) at –78 °C under argon was added to the 
reaction mixture via a cannula. After 40 min, Et3N (1.2 mL, 0.87 g, 8.6 mmol) was added and the 
cooling bath was removed. After 30 min, the mixture was diluted with CH2Cl2 and washed 
sequentially with saturated aq NH4Cl, saturated aq NaHCO3 and brine, dried over Na2SO4, 
concentrated, and fractionated by FCC (10% ethyl acetate in hexane) to give the title compound 
(673 mg, 92%). 
white amorphous solid, TLC Rf = 0.3 (20% ethyl acetate in hexane);  
*α+D +72 (c 1.2, CHCl3);  
IR max: 1727 cm
-1
;  
1H NMR (CDCl3) : 9.92 (1H, d, J = 1.5 Hz, HC=O), 7.45-7.32 (5H, m, Ph), 5.61 (1H, s, HC-2), 3.79 
(1H, dd, J = 10, 10 Hz, HC-8a), 3.47 (1H, dd, J = 2, 10 Hz, HC-4), 2.98 (1H, dddd, J = 1.5, 4, 10, 11 
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Hz, HC-8), 2.84-2.71 (2H, m, H2C-7), 2.51 (1H, br d, J = 13 Hz, HC-5), 2.36 (1H, br dd, J = 10, 13 
Hz, HC-5), 2.15 (1H, dddd, J = 3, 10, 10, 12 Hz, HC-4a), 1.94 (1H, dqq, J = 2, 7, 7 Hz, HC-1'), 1.08 
(3H, d, J = 7 Hz, H3C-2'), 1.01 (3H, d, J = 7 Hz, H3C-2');  
13C NMR (CDCl3) : 202.7 (d, C=O), 138.3 (s, Ph), 129.0 (d, Ph), 128.4 (d ×2, Ph), 126.1 (d ×2, Ph), 
100.8 (d, C-2), 83.9 (d, C-4), 81.2 (d, C-8a), 54.6 (d, C-8), 43.5 (d, C-4a), 28.5 (d, C-1'), 27.4 (t, C-
5), 27.1 (t, C-7), 20.1 (q, C-2'), 15.1 (q, C-2');  
HRMS m/z calcd. for C17H22O3S 306.1290, found 306.1284 (EI). 
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(3R)-rel-3-[(S)-(6S)-1,4-Dioxa-8-thiaspiro[4.5]dec-6-yl(benzyloxymethoxy)methyl]tetrahydro-
4H-thiopyran-4-one (126). 
 
126  
 Diisopropylethylamine (3.8 mL, 18 mmol) and benzyl chloromethyl ether (2.5 mL, 18 
mmol) were added to a stirred solution of 98 (1.11 g, 3.65 mmol) and in DMF (10 mL) at room 
temperature under Ar. After 16 h, a second portion of diisopropylethylamine (1.3 mL, 6.2 
mmol) and benzyl chloromethyl ether (1.0 mL, 7.3 mmol) were added. After 5 h (reaction 
complete by TLC analysis), the reaction was quenched by addition of MeOH (20 mL). After 1 h, 
the mixture was diluted with ethyl acetate and washed sequentially with saturated aq NH4Cl, 
water and brine, dried over Na2SO4, concentrated, and fractionated by FCC (20% ethyl acetate 
in hexane) to furnish the title compound (1.34 g, 87%).  
colorless oil, TLC Rf = 0.3 (20% ethyl acetate in hexane);  
IR max: 1708 cm
-1
;  
1H NMR (CDCl3) : 7.40-7.22 (5H, m, Ph), 4.88 (1H, d, J = 7 Hz, HCO2), 4.77 (1H, d, J = 7 Hz, 
HCO2), 4.62 (1H, dd, J = 1.5, 8 Hz, HC-1'), 4.58 (1H, d, J = 12 Hz, HCPh), 4.52 (1H, d, J = 12 Hz, 
HCPh), 4.12-3.87 (4H, m, H2C-2', H2C-3'), 3.12 (1H, ddd, J = 1.5, 5.5, 13.5 Hz, HC-2), 3.07 (1H, 
ddd, J = 3.5, 5.5, 8 Hz, HC-3), 2.99 (1H, dd, J = 3.5, 13.5 Hz, HC-2), 2.95-2.73 (6H, m, HC-5, H2C-6 
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H2C-7', HC-9'), 2.63-2.48 (2H, m, HC-5, HC-9'), 2.42 (1H, ddd, J = 2, 3.5, 10.5 Hz, HC-6'), 2.12 (1H, 
ddd, J = 3, 5, 13.5 Hz, HC-10'), 1.73 (1H, ddd, J = 3.5, 12, 13.5 Hz, HC-10');  
13C NMR (CDCl3) : 209.4 (s, C-4), 137.9 (s, Ph), 128.6 (d ×2, Ph), 128.0 (d ×2, Ph), 127.9 (d, Ph), 
108.5 (s, C-5'), 94.8 (t, OCH2O), 76.8 (d, C-1'), 70.5 (t, CH2Ph), 64.6 (t, C-2'), 64.3 (t, C-3'), 54.8 (d, 
C-3), 50.5 (d, C-6'), 43.2 (t, C-5), 36.6 (t, C-10'), 33.7 (t, C-2), 31.0 (t, C-6), 29.1 (t, C-7'), 26.9 (t, C-
9');  
HRMS m/z calcd. for C21H32O5+Na
+ 447.1270, found 447.1281 (ESI). 
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(3R,5R)-3-((S)-((S)-1,4-dioxa-8-thiaspiro[4.5]decan-6-yl)((triethylsilyl)oxy)methyl)-5-((R)-
hydroxy((2S,4S,4aS,8R,8aR)-4-isopropyl-2-phenylhexahydrothiopyrano[4,3-d][1,3]dioxin-8-
yl)methyl)dihydro-2H-thiopyran-4(3H)-one (136). 
 
136 
 (c-Hex)2BCl (1.07 M in hexane; 4.5 mL, 4.8 mmol) and by Et3N (0.71 mL, 0.52 g, 5.1 
mmol) were sequentially added to a stirred solution of 127 (1.02 g, 2.44 mmol) in CH2Cl2 (3 mL) 
at –45 °C under argon. After 2 h, t-BuNH2 (0.51 mL, 0.35 g, 4.9 mmol) was added. After 1 h, the 
mixture was cooled to –78 °C, and a solution of 124 (247 mg, 0.81 mmol) in CH2Cl2 (2 mL) 
added. After 8 h, the reaction was quenched by the addition of phosphate buffer (pH = 7; 1 M, 
5 mL), methanol (5 mL), and 30% aq H2O2 (2.5 mL) with vigorous stirring. The reaction vessel 
was transferred to an ice bath and, after vigorous stirring for 20 min, the mixture was diluted 
with water and extracted with CH2Cl2. The combined organic layers were dried over Na2SO4 and 
concentrated to give a yellow oil whose 1H NMR spectrum suggested the presence of a 15:1 
mixture of aldol adducts. The crude material was fractionated by FCC (20% ethyl acetate in 
hexane) to give recovered 127 (612 mg, 60%) and the title compound (468 mg, 80%).  
pale yellow oil, TLC Rf = 0.3 (30% ethyl acetate in hexane);  
*α+D –19 (c 1.1, CHCl3);  
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IR max: 3555, 1699 cm
-1
;  
1H NMR (CDCl3) : 7.52-7.28 (5H, m, Ph), 5.63 (1H, s, HC-2''), 4.85 (1H, br d, J = 6 Hz, HC-1'), 4.48 
(1H, br d, J = 9.5 Hz, HC-1''), 4.08-3.83 (4H, m, H2C-2', H2C-3'), 3.80 (1H, dd, J = 10, 10 Hz, HC-
8a''), 3.43 (1H, dd, J = 2, 9.5 Hz, HC-4''), 3.16 (1H, d, J = 3 Hz, HO), 3.17-3.12 (1H, ddd, HC-2), 
3.07 (1H, ddd, J = 4.5, 5, 6 Hz, HC-3), 2.97-2.72 (7H, m, HC-2, HC-5, HC-6, H2C-7' HC-9', HC-7''), 
2.62-2.41 (4H, m, HC-6, HC-9', HC-5'', HC-7''), 2.41-2.32 (2H, m, HC-6', HC-5''), 2.14 (1H, br d, J = 
14 Hz, HC-10'), 2.09-1.92 (3H, m, HC-4a'', HC-8'', HCC-4''), 1.66 (1H, ddd, J = 3.5, 12.5, 14 Hz, HC-
10'), 1.09 (3H, 7, J = 7 Hz, H3CCC-4''), 0.98 (3H, d, J = 7 Hz, H3CCC-4''), 0.97 (9H, t, J = 8 Hz, H3CCSi 
×3), 0.73-0.62 (6H, m, H2CSi ×3);  
13C NMR (CDCl3) : 213.3 (s, C-4), 139.1 (s, Ph), 128.7 (d, Ph), 128.3 (d ×2, Ph), 126.1 (d ×2, Ph), 
108.6 (d, C-5'), 100.6 (d, C-2''), 83.8 (d, C-4''), 79.3 (d, C-8a''), 70.7 (d, C-1'), 67.4 (d, C-1''), 64.4 
(t, C-2'), 64.0 (t, C-3'), 55.1 (d, C-3), 54.5 (d, C-6'), 53.0 (d, C-5), 44.1 (d ×2, C-4a'', C-8''), 36.9 (t, 
C-10'), 33.2 (t, C-2), 31.1 (t, C-6), 28.5 (d, CHC-4''), 27.5 (t, C-5''), 27.2 (t, C-7'), 26.9 (t, C-9'), 25.7 
(t, C-7''), 20.3 (q, CH3CC-4''), 15.1 (q, CH3CC-4''), 7.2 (q, CH3CSi), 5.4 (t, CH2Si);  
HRMS m/z calcd. for C36H56O7S3Si+Na
+ 747.2850, found 747.2853 (ESI). 
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(1S,2R)-rel-1-Hydroxy-2-methyl-1-((S)-1,4-dioxa-8-thiaspiro[4.5]decan-6-yl)pentan-3-one 
(147aa). 
 
147aa 
 MgBr2·OEt2 (8.35 g, 32.4 mmol) was added to a stirred solution of 74 (2.98 g, 15.9 mmol) 
and 149 (Z:E ca. 5:1; 4.44 g, 28.1 mmol) in CH2Cl2 (125 mL) at 0 °C under argon. After 1 h 
(reaction complete by TLC analysis), the reaction was quenched by addition of ice-cold 
phosphate buffer (pH 6.8, 100 mL) with vigorous stirring. After 15 min, the organic layer was 
removed, and the aq layer was extracted with CH2Cl2. The combined organic layers were dried 
over Na2SO4 and concentrated to give the crude product as a pale yellow oil whose 
1H NMR 
spectrum indicated the presence of a 4:1 mixture of the title compound and its C2 epimer 
147sa, respectively. Fractionation of the crude product by FCC (60% Et2O in hexane) gave the 
titled compound (2.83 g, 65%). 
pale yellow viscous oil, TLC Rf = 0.45 (50% ethyl acetate in hexane); 
IR max: 3495, 1698 cm
-1
;  
1H NMR (CDCl3) : 4.16-4-10 (2H, m, HO, HC-1), 4.03-3.95 (4H, m, H2C-2', H2C-3'), 2.87 (1H, dd, J 
= 3, 14 Hz, HC-7'), 2.80 (1H, dq, J = 4.5, 7 Hz, HC-2), 2.74 (1H, dd, J = 7.5, 14 Hz, HC-7'), 2.71 (1H, 
ddd, J = 3.5, 8.5, 13.5 Hz, HC-9'), 2.65 (1H, ddd, J = 3.5, 7.5, 13.5 Hz, HC-9'), 2.61-2.48 (2H, m, 
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H2C-4), 2.13 (1H, , J = 3, 8.5, 13.5 Hz, HC-10'), 2.01 (1H, ddd, J = 3, 7, 7.5 Hz, HC-6'), 1.75 (1H, 
ddd, J = 3.5, 7.5, 13.5 Hz, HC-10'), 1.21 (3H, d, J = 7 Hz, H3CC-2), 0.99 (3H, t, J = 7 Hz, C-1);  
13C NMR (CDCl3) : 215.2 (s, C-3), 110.6 (s, C-5'), 74.6 (d, C-1), 64.7 (t, C-2'), 64.0 (t, C-3'), 49.4 
(d, C-2), 46.5 (d, C-6'), 35.3 (t, C-4), 34.7 (t, C-10'), 30.0 (t, C-7'), 26.8 (t, C-9'), 14.2 (q, CH3C-2), 
7.7 (q, C-5);  
HRMS m/z calcd. for C13H22O4S 274.1239, found 274.1237 (EI). 
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(4R,5S,6S)-rel-5-(t-Butyldimethylsilyl)oxy-6-(2-ethyl-1,3-dioxolan-2-yl)-4-methylheptan-3-one 
(150). 
 
150 
 t-Butyldimethylchlorosilane (4.7 g, 31 mmol) was added to a stirred solution of 99 (5.08 
g, 20.8 mmol) and Et3N (5.8 mL, 4.2 g, 42 mmol) in DMF (50 mL) at room temperature. After 18 
h, the mixture was diluted with ethyl acetate and washed sequentially with saturated aq NH4Cl, 
water and brine, dried over Na2SO4, concentrated, and fractionated by FCC (10% ethyl acetate 
in hexane) to give the title compound as a yellow oil (7.16 g, 96%). 
pale yellow oil, TLC Rf = 0.3 (10% ethyl acetate in hexane);  
IR max: 1718 cm
-1
;  
1H NMR (CDCl3) : 4.03 (1H, dd, J = 2.5, 6.5 Hz, HC-5), 3.98-3.85 (4H, m, H2C-4' H2C-5'), 2.93 (1H, 
dq, J = 6.5, 7 Hz, HC-4), 2.61-2.42 (2H, m, H2C-2), 2.08 (1H, dq, J = 2.5, 7 Hz, HC-6), 1.68 (2H, ap 
q, J = 7.5 Hz, H2C-1''), 1.05 (3H, d, J = 7 Hz, H3CC-4), 1.01 (3H, d, J = 7 Hz, H3C-7), 1.00 (3H, t, J = 7 
Hz, H3C-1), 0.87 (3H, t, J = 7.5 Hz, H3C-2''), 0.83 (9H, s, (H3C)3C), 0.06 (3H, s, H3CSi), 0.01 (3H, s, 
H3CSi);  
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13C NMR (CDCl3) : 214.8 (s, C-3), 113.2 (s, C-2'), 75.6 (d, C-5), 65.7 (t, C-4'), 65.1 (t, C-5'), 49.0 
(d, C-4), 45.4 (d, C-6), 36.8 (d, C2), 29.1 (q, C-1''), 26.2 (q ×3, (CH3)3C), 18.4 (s, CSi), 15.6 (q, CH3C-
4), 10.2 (q, C-7), 8.1 (q, C-2''), 7.7 (q, C-1), –4.2 (q, CH3Si), –4.6 (q, CH3Si);  
HRMS m/z calcd. for C19H38O4Si+H 359.2618, found 359.2616 (CI, NH3). 
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(4R,5S,6S)-rel-5-(Benzyloxy)methoxy-6-(2-ethyl-1,3-dioxolan-2-yl)-4-methylheptan-3-one 
(151). 
 
151 
 PhCH2OCH2Cl (purity ca. 75%; 2.5 mL, 2.8 g, 13 mmol) was added to a stirring solution of 
99 (2.21 g, 9.06 mmol) and i-Pr2EtN(4.0 mL, 3.0 g, 23 mmol) in DMF (50 mL) at room 
temperature. After 18 h, a second addition of i-Pr2EtN (4.0 mL, 3.0 g, 23 mmol) and 
PhCH2OCH2Cl (purity ca. 75%; 2.5 mL, 2.8 g, 13 mmol). After 6 h (reaction complete by TLC 
analysis), the reaction was quenched by addition of methanol (20 mL). After 1 h, the mixture 
was diluted with ethyl acetate and washed sequentially with saturated aq NH4Cl, water and 
brine, dried over Na2SO4, concentrated, and fractionated by FCC (10% ethyl acetate in hexane) 
to give the title compound (3.01 g, 91%). 
yellow oil, TLC Rf = 0.3 (15% ethyl acetate in hexane);  
IR max: 1714 cm
-1
;  
1H NMR (CDCl3) : 7.40-7.22 (5H, m, Ph), 4.68 (1H, d, J = 6.5 Hz, HCO2), 4.66 (1H, d, J = 6.5 Hz, 
HCO2), 4.58 (1H, d, J = 12 Hz, HCPh), 4.52 (1H, d, J = 12 Hz, HCPh), 4.01-3.92 (4H, m, H2C-4', H2C-
5'), 3.84 (1H, dd, J = 3, 8 Hz, HC-5), 3.17 (1H, dq, J = 7, 8 Hz, HC-4), 2.52 (2H, m, J = 7.5, 18 Hz, 
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H2C-2), 2.19 (1H, dq, J = 3, 7 Hz, HC-6), 1.84-1.68 (2H, m, H2C-1''), 1.07 (3H, d, J = 7 Hz, H3CC-4), 
1.06 (3H, d, J = 7 Hz, H3C-7), 1.02 (3H, t, J = 7 Hz, H3C-1), 0.89 (3H, t, J = 7.5 Hz, H3C-2'');  
13C NMR (CDCl3) : 215.0 (s, C-3), 138.2 (s, Ph), 128.6 (d ×2, Ph), 128.0 (d ×2, Ph), 127.8 (d, Ph), 
113.6 (s, C-2'), 96.1 (t, OCH2O), 83.2 (d, C-5), 70.4 (t, CH2Ph), 65.5 (t, C-4'), 65.3 (t, C-5'), 48.7 (d, 
C-4), 41.8 (d, C-6), 37.1 (t, C-2), 28.9 (t, C-1''), 14.8 (q, CH3C-4), 12.4 (q, C-7), 7.8 (q ×2, C-1, C-
2'');  
HRMS m/z calcd. for C21H32O5+Na
+ 387.2143, found 387.2133 (ESI). 
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(1S,2S,4R,5S,6S)-5-((tButyldimethylsilyl)oxy)-6-(2-ethyl-1,3-dioxolan-2-yl)-1-hydroxy-1-
((2S,4S,4aS,8R,8aR)-4-isopropyl-2-phenylhexahydrothiopyrano[4,3-d][1,3]dioxin-8-yl)-2,4-
dimethylheptan-3-one (152). 
 
152 
 A solution of LiHMDS was prepared by addition of n-BuLi (2.3 M in hexane; 1.3 
mL, 3.0 mmol) was added to a stirred solution of (Me3Si)2NH (0.65 mL, 0.50 g, 3.1 mmol) in THF 
(10 mL) at 0°C under argon. After 15 minutes, the reaction mixture was cooled to –78°C and a 
solution of 150 (1.06 g, 2.96 mmol) in THF (5 mL) was added dropwise via syringe over 5 min. 
After 15 min, the mixture was warmed to –50 °C and stirring continued for 90 min. The mixture 
was cooled to –78 °C and a solution of TiCl(Oi-Pr)3 (0.73 M in CH2Cl2; 8.9 mL, 6.5 mmol) was 
added dropwise via syringe over 5 min. After 15 min, mixture was warmed to –50 °C and 
stirring continued for 90 min. The reaction mixture was cooled –78 °C and a solution of 124 
(305 mg, 0.997 mmol) in THF (2 mL) was added dropwise via a syringe. After 5 h, the reaction 
was quenched by addition of saturated aq NH4Cl. The mixture was extracted with Et2O and the 
combined organic layers were dried over Na2SO4 and concentrated to give the crude product 
whose 1H NMR spectrum indicated the presence of a 4:1 mixture of aldol adducts. The crude 
product was fractionated by FCC (20% ethyl acetate in hexane) to the title compound as an 
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inseparable 4:1 mixture of diastereomers (553 mg, 84%) as a colorless oil. colorless oil, TLC Rf = 
0.3 (20% ethyl acetate in hexane);  
1H NMR (CDCl3)  (* denotes signals from the minor diastereomer): 7.55-7.28 (5H, m, Ph), 5.63* 
(0.2H, s, HC-2'), 5.52 (0.8H, s, HC-2'), 4.45* (0.2H, dd, J = 1, 9.5 Hz, HC-1), 4.24 (0.8H, br dd, J = 
2, 6 Hz, HC-1), 4.19* (0.2H, dd, J = 2, 9 Hz, HC-5), 4.07 (0.8H, dd, J = 2.5, 7 Hz, HC-5), 4.05-3.80 
(4H, m, H2C-4'', H2C-5''), 3.72* (0.2H, dd, J = 10, 10 Hz, HC-8a'), 3.48 (0.8H, dd, J = 10, 10 Hz, HC-
8a'), 3.45* (0.2H, dd, J = 2, 10 Hz, HC-4'), 3.38 (0.8H, dd, J = 2, 10 Hz, HC-4'), 3.34 (0.8H, bs, HO), 
3.18* (0.2H, dq, J = 7, 7 Hz), 3.11 (0.8H, dq, J = 2.5, 7 Hz, HC-2), 3.08-2.98 (1.6H, m, HC-4, HC-7'), 
2.87* (0.2H, dd, J = 12.5, 13.5 Hz), 2.74* (0.2H, dq, J = 9.5, 7 Hz), 2.65 (0.8H, dd, J = 11, 14 Hz, 
HC-7'), 2.51 (0.8H, m, HC-5'), 2.47* (0.2H, m, HC-5'), 2.35* (0.2H, dd, J = 12, 13 Hz, HC-5'), 2.29 
(0.8H, dd, J = 12, 13 Hz, HC-5'), 2.15-2.02 (3H, m, HC-6, HC-4a', HC-8'), 2.00-1.90 (1H, m, HCC-
4'), 1.75-1.65 (2H, m, H2CC-2''), 1.19 (2.4H, d, J = 7 Hz, H3CC-2), 1.11* (0.6H, d, J = 7 Hz), 1.10* 
(0.6H, d, J = 7 Hz), 1.06* (0.6H, d, J = 7 Hz), 1.05 (2.4H, d, J = 7 Hz, H3CCC-4'), 1.01 (2.4H, d, J = 7 
Hz, H3CC-4), 0.98 (0.6H, d, J = 7 Hz), 0.96 (2.4H, d, J = 7 Hz, H3CCC-4'), 0.93-0.83 (6H, m, H3C-7, 
H3CCC-2''), 0.82 (9H, s, (H3C)3C), 0.11 (0.6H, s, CH3Si), 0.05 (2.4H, s, CH3Si), –0.02 (0.6H, s, CH3Si), 
–0.05 (2.4H, s, CH3Si);  
13C NMR (CDCl3)  (minor isomer): 217.6 (s, C-3), 139.1 (s, Ph), 128.6 (d, Ph), 128.2 (d 2, Ph), 
126.0 (d 2, Ph), 113.2 (d, C-2''), 100.3 (d, C-2'), 83.9 (d, C-4'), 79.8 (d, C-8a'), 74.5 (d, C-5), 69.3 
(d, C-1), 65.7 (t, C-4''), 64.9 (t, C-5''), 48.9, 48.2, 45.5, 44.6, 44.0, 29.4, 28.47, 27.5, 26.3, 25.8, 
20.3, 18.5, 15.2, 15.1, 12.9, 10.2, 8.2, –3.8, –4.6;  (major isomer): 219.9 (s, C-3), 139.0 (s, Ph), 
128.8 (d, Ph), 128.3 (d 2, Ph), 126.3 (d 2, Ph), 112.9 (s, C-2''), 101.0 (d, C-2'), 84.0 (d, C-4'), 
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82.2 (d, C-8a'), 75.5 (d, C-5), 70.4 (d, C-1), 65.8 (t, C-4''), 64.8 (t, C-5''), 51.2 (d, C-2), 46.7 (d, C-4), 
46.1 (d 2, C-6, C-8'), 43.8, 29.3 (t, CH2C-2"), 29.1 (t, C-7'), 28.45 (d, CHC-4'), 27.5 (t, C-5'), 26.3 
(q 3, (CH3)3C), 20.2 (q, CH3CC-4'), 18.4 (s, CSi), 15.7 (q, H3CC-4), 15.0 (q, CH3CC-4'), 10.4 (q, 
H3CC-2), 9.4 (q, C-7), 8.3 (q, CH3CC-2''), –4.2 (q, CH3Si), –4.5 (q, CH3Si); 
HRMS m/z calcd. for C36H60O7SiS+Na
+ 687.3721, found 687.3743 (ESI). 
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(1S,2S,4R,5S,6S)-5-((Benzyloxy)methoxy)-6-(2-ethyl-1,3-dioxolan-2-yl)-1-hydroxy-1-
((2S,4S,4aS,8R,8aR)-4-isopropyl-2-phenylhexahydrothiopyrano[4,3-d][1,3]dioxin-8-yl)-2,4-
dimethylheptan-3-one (153). 
 
153 
 A solution of LiHMDS was prepared by addition of n-BuLi (2.3 M in hexane; 1.2 mL, 2.8 
mmol) was added dropwise via a syringe to a stirred solution of (Me3Si)2NH (0.64 mL, 0.50 g, 3.1 
mmol) in THF (10 mL) at 0 °C under argon. After 15 min, the solution was cooled to –78 °C and a 
solution of 151 (963 mg, 2.65 mmol) in THF (5 mL) was added dropwise via a syringe over 5 
minutes. After 15 min, the solution was warmed to –50 °C and stirred at this temperature for 
90 min. The reaction mixture was cooled to –78 °C and TiCl(Oi-Pr)3 (0.73 M in THF; 7.3 mL, 5.3 
mmol) was added dropwise via a syringe over 5 min. After 15 min, the mixture was warmed to 
–50°C and stirred at this temperature for 90 min. The reaction mixture was cooled to –78 °C 
and a solution of 124 (250 mg, 0.817 mmol) in THF (2 mL) was added via a syringe. After 5 h, the 
reaction was quenched by addition of saturated aq NH4Cl. The mixture was diluted with water 
and extracted with Et2O. The combined organic layers were dried over Na2SO4, and 
concentrated to give the crude product whose 1H NMR spectrum indicated the presence of a 
7:1 mixture of aldol adducts along with 124 (ca. 95% conversion) and 151. The crude product 
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was fractionated by FCC (20% ethyl acetate in hexane) to give recovered 151 [678 mg, 70%; *α+D 
+5.2 (c 2.3, CHCl3)] and the title compound (431 mg, 79%). 
colorless oil, TLC Rf = 0.3 (30% Et2O in toluene);  
*α+D +0.60 (c 1.2, CHCl3);  
IR max: 3499, 1707 cm
-1
;  
1H NMR (CDCl3) : 7.51-7.20 (10H, m, Ph ×2), 5.55 (1H, s, HC-2'), 4.60 (2H, ap s, OCH2O), 4.49 
(1H, d, J = 12 Hz, H2CPh), 4.43 (1H, d, J = 12 Hz, H2CPh), 4.40 (1H, ddd, J = 3.5, 4, 4 Hz, HC-1), 
3.96-3.83 (4H, m, H2C-4'', H2C-5''), 3.82 (1H, dd, J = 2, 9 Hz, HC-5), 3.51 (1H, dd, J = 9.5, 10 Hz, 
HC-8a'), 3.36 (1H, dd, J = 2, 10 Hz, HC-4'), 3.34 (1H, dq, J = 9, 7 Hz, HC-4), 3.04 (1H, dq, J = 3.5, 7 
Hz, HC-2), 2.93 (1H, d, J = 4 Hz, HO), 2.88 (1H, ddd, J = 2.5, 3, 14 Hz, HC-7'), 2.67 (1H, dd, J = 
11.5, 14 Hz, HC-7'), 2.47 (1H, ddd, J = 2.5, 3, 13.5 Hz, HC-5'), 2.29 (1H, dd, J = 12, 13.5 Hz, HC-5'), 
2.18 (1H, dq, J = 2, 7 Hz, HC-6), 2.14 (1H, dddd, J = 3, 4, 10, 11.5 Hz, HC-8'), 2.06 (1H, dddd, J = 
3.5, 9.5, 10, 12 Hz, HC-4a'), 1.93 (1H, ddq, J = 2, 7, 7 Hz, HCC-4'), 1.76-164 (2H, m, H2CC-2''), 1.15 
(3H, d, J = 7 Hz, H3CC-2), 1.05 (3H, d, J = 7 Hz, H3CCC-4'), 1.02 (3H, d, J = 7 Hz, H3C-7), 0.98 (3H, d, 
J = 7 Hz, H3CC-4), 0.95 (3H, d, J = 7 Hz, H3CCC-4'), 0.86 (3H, t, J = 7.5 Hz, H3CCC-2'');  
13C NMR (CDCl3) : 218.3 (s, C-3), 139.0 (s, Ph), 138.0 (s, Ph), 128.8 (d, Ph), 128.6 (d ×2, Ph), 
128.3 (d ×2, Ph), 128.0 (d ×2, Ph), 127.8 (d, Ph), 126.3 (d ×2, Ph), 113.4 (s, C-2''), 101.0 (d, C-2'), 
96.1 (t, OCH2O), 84.0 (d, C-4'), 83.2 (d, C-5), 82.7 (d, C-8a'), 70.7 (t, CH2Ph), 69.5 (d, C-1), 65.6 (t, 
C-4''), 65.1 (t, C-5''), 51.8 (d, C-2), 46.9 (d, C-4), 46.1 (d, C-8'), 43.9 (d, C-4a'), 41.6 (d, C-6), 29.0 
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(t, CH2C-2''), 28.44 (d, CHC-4'), 28.39 (t, C-7'), 27.5 (t, C-5'), 20.2 (q, CH3CC-4'), 15.3 (q, CH3C-4), 
15.0 (q, CH3CC-4'), 12.0 (q, C-7), 10.2 (q, CH3CC-2), 7.9 (q, CH3CC-2'');  
HRMS m/z calcd. for C38H54O8S 670.3539, found 670.3586 (FD). 
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(1S,2S,4R,5R,6S)-5-((tButyldimethylsilyl)oxy)-1-hydroxy-1-((2S,4S,4aS,8R,8aR)-4-isopropyl-2-
phenylhexahydrothiopyrano[4,3-d][1,3]dioxin-8-yl)-2,4,6-trimethylnonane-3,7-dione (154). 
 
154 
 p-TsOH·H2O (32 mg, 0.16 mmol) was added to a stirred solution of 152 (4:1 mixture of 
diastereomers; 553 mg, 0.833 mmol) in acetone (20 mL) at ambient temperature. After 16 h, 
the reaction was quenched by the addition of saturated aq NaHCO3 and the mixture was 
extracted with CH2Cl2. The combined organic layers were dried over Na2SO4, concentrated, and 
fractionated by FCC (20% ethyl acetate in hexane) to give 154a (94 mg, 18%) and the title 
compound (357 mg, 69%).  
colorless oil, TLC Rf = 0.3 (20% ethyl acetate in hexane);  
*α+D +2.0 (c 1.2, CHCl3);  
IR max: 3510, 1709 cm
-1
;  
1H NMR (CDCl3) : 7.50-7.30 (5H, m, Ph), 5.52 (1H, s, HC-2'), 4.43 (1H, dd, J = 5.5, 7 Hz, HC-5), 
4.18 (1H, ddd, J = 3, 3, 6 Hz, HC-1), 3.48 (1H, dd, J = 9.5, 9.5 Hz, HC-8a'), 3.38 (1H, dd, J = 2, 10 
Hz, HC-4'), 3.16 (1H, dq, J = 3, 7 Hz, HC-2), 2.94 (1H, d, J = 3.4 Hz, HO), 2.93 (1H, ddd, J = 2.5, 3, 
14 Hz, HC-7'), 2.82 (1H, dq, J = 7, 7 Hz, HC-4), 2.68-2.62 (2H, m, HC-6, HC-7'), 2.55-2.38 (3H, m, 
H2C-8, HC-5'), 2.30 (1H, dd, J = 12, 13 Hz, HC-5'), 2.22-2.05 (2H, m, HC-4a', HC-8'), 1.94 (1H, dqq, 
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J = 2, 7, 7 Hz, HC-1''), 1.17 (3H, d, J = 7 Hz, H3CC-2), 1.08 (3H, d, J = 7 Hz, H3CC-1''), 1.02 (3H, t, J = 
7.5 Hz, H3C-9), 0.97 (3H, d, J = 7 Hz, H3CC-1''), 0.89 (3H, d, J = 7 Hz, H3CC-6), 0.82 (3H, d, J = 7 Hz, 
H3CC-4), 0.80 (9H, s, (H3C)3CSi), 0.04 (3H, s, H3CSi), –0.03 (3H, s, H3CSi);  
13C NMR (CDCl3) : 217.9 (s, C-3), 212.1 (s, C-7), 138.9 (s, Ph), 128.9 (s, Ph), 128.3 (d ×2, Ph), 
126.3 (d ×2, Ph), 101.2 (d, C-2'), 84.0 (d, C-4'), 82.2 (d, C-8a'), 74.4 (d, C-5), 70.1 (d, C-1), 51.5 (d, 
C-6), 50.1 (d, C-2), 49.1 (d, C-4), 46.2 (d, C-8'), 43.8 (d, C-4a'), 35.7 (t, C-8), 28.7 (t, C-7'), 28.5 (d, 
C-1''), 27.5 (t, C-5'), 26.0 (q ×3, (CH3)3C), 20.2 (q, CH3C-1''), 18.2 (s, CSi), 15.0 (q, CH3C-1''), 12.2 
(q, CH3C-4), 11.1 (q, CH3C-2), 10.6 (q, CH3C-6), 7.8 (q, C-9), –4.4 (q, CH3Si), –4.7 (q, CH3Si);  
HRMS m/z calcd. for C34H56O6SSi+Na
+ 643.3459, found 643.3465 (ESI). 
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(1S,2S,4S,5S,6R)-5-((tButyldimethylsilyl)oxy)-1-hydroxy-1-((2S,4S,4aS,8R,8aR)-4-isopropyl-2-
phenylhexahydrothiopyrano[4,3-d][1,3]dioxin-8-yl)-2,4,6-trimethylnonane-3,7-dione (154a). 
 
154a 
See the preparation of 154.  
colorless oil, TLC Rf = 0.3 (15% ethyl acetate in hexane);  
*α+D +15 (c 1.2, CHCl3);  
IR max: 3510, 1710 cm
-1
;  
1H NMR (CDCl3) : 7.50-7.30 (5H, m, Ph), 5.52 (1H, s, HC-2'), 4.54 (1H, dd, J = 5.5, 7 Hz, HC-5), 
4.37 (1H, ddd, J = 2, 5, 9.5 Hz, HC-1), 3.65 (1H, dd, J = 9.5, 10 Hz, HC-8a'), 3.43 (1H, dd, J = 2, 10 
Hz, HC-4'), 2.94 (1H, dq, J = 7, 7 Hz, HC-4), 2.84 (1H, dq, J = 7, 10 Hz, HC-2), 2.82 (1H, dd, J = 12, 
14 Hz, HC-7'), 2.74 (1H, dq, J = 5.5, 7 Hz, HC-6), 2.61-2.43 (4H, m, H2C-8, HC-5', HC-7'), 2.41 (1H, 
d, J = 5 Hz, HO), 2.37 (1H, dd, J = 12, 13.5 Hz, HC-5'), 2.13-2.04 (2H, m, HC-4a', HC-8'), 1.96 (1H, 
dqq, J = 2, 7, 7 Hz, HC-1''), 1.10 (3H, d, J = 7 Hz, H3CC-1''), 1.04 (3H, d, J = 7 Hz, H3CC-2), 1.02 (3H, 
t, J = 7.5 Hz, H3C-9), 0.99 (3H, d, J = 7 Hz, H3CC-6), 0.97 (3H, d, J = 7 Hz, H3CC-1''), 0.90 (3H, d, J = 
7 Hz, H3CC-4), 0.84 (9H, s, (H3C)3C), 0.08 (3H, s, H3CSi), 0.03 (3H, s, H3CSi);  
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13C NMR (CDCl3) : 216.0 (s, C-3), 212.6 (s, C-7), 138.9 (s, Ph), 128.7 (s, Ph), 128.3 (d ×2, Ph), 
126.1 (d ×2, Ph), 100.5 (d, C-2'), 84.0 (d, C-4'), 79.9 (d, C-8a'), 73.5 (d, C-5), 70.2 (d, C-1), 51.5 (d, 
C-6), 51.1 (d, C-4), 47.8 (d, C-2), 44.8 (d, C-8'), 43.9 (d, C-4a'), 35.8 (t, C-8), 28.5 (d, C-1''), 27.5 (t, 
C-5'), 26.0 (q ×3, (CH3)3C), 25.8 (t, C-7'), 20.3 (q, CH3C-1''), 18.2 (s, CSi), 15.1 (q, CH3C-1''), 13.2 
(q, CH3C-2), 11.7 (q, CH3C-6), 10.8 (q, CH3C-4), 7.8 (q, C-9), –4.2 (q, CH3Si), –4.8 (q, CH3Si);  
HRMS m/z calcd. for C34H56O6SSi+Na
+ 643.3459, found 643.3469 (ESI). 
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(4S,5R,6R,8S,9R,10R)-5-((tButyldimethylsilyl)oxy)-9-hydroxy-10-((2S,4R,5S,6S)-6-isopropyl-5-
methyl-2-phenyl-1,3-dioxan-4-yl)-4,6,8-trimethylundecane-3,7-dione (155a). 
 
155a 
 A suspension of Raney nickel (W2; 4 mL settled volume) in EtOH (10 mL) was added to a 
solution of 154 (357 mg, 0.538 mmol) in EtOH (5 mL) and the resulting mixture was heated 
under reflux with vigorous stirring. After 4 h (reaction was complete by TLC analysis), the 
mixture was decanted, and the solid was suspended in ethyl acetate (10 mL) and heated under 
reflux with vigorous stirring for several min. This washing procedure was repeated with acetone 
(×2) and MeOH. The combined organic layers were filtered through Celite, concentrated, and 
fractionated by FCC (25% ethyl acetate in hexane) to give the title compound (291 mg, 85%).  
colorless oil, TLC Rf = 0.3 (15% ethyl acetate in hexane);  
*α+D –16 (c 0.80, CHCl3);  
IR max: 3523, 1708 cm
-1
;  
1H NMR (CDCl3) : 7.50-7.30 (5H, m, Ph), 5.45 (1H, s, HC-2'), 4.40 (1H, dd, J = 2.5, 8.5 Hz, HC-5), 
4.24 (1H, br d, J = 10 Hz, HC-9), 3.48 (1H, dd, J = 1.5, 9.5 Hz, HC-4'), 3.30 (1H, dd, J = 2, 10 Hz, 
HC-6'), 3.28 (1H, br s, HO), 2.94 (1H, dq, J = 9.5, 7 Hz, HC-8), 2.88 (1H, dq, J = 2.5, 7 Hz, HC-6), 
2.82 (1H, dq, J = 8.5, 7 Hz, HC-4), 2.52 (1H, dq, J = 18.5, 7 Hz, HC-2), 2.46 (1H, dq, J = 18.5, 7 Hz, 
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HC-2), 2.12-1.98 (2H, m, HC-5', HC-1''), 1.92 (1H, br q, J = 7 Hz, HC-10), 1.27 (3H, d, J = 7 Hz, 
H3CC-8), 1.16 (3H, d, J = 7 Hz, H3CC-10), 1.14 (3H, d, J = 7 Hz, H3CC-6), 1.08 (3H, d, J = 7 Hz, H3CC-
1''), 1.02 (3H, t, J = 7 Hz, H3C-1), 0.88 (3H, d, J = 7 Hz, H3CC-1''), 0.85 (9H, s, (H3C)3C), 0.83 (3H, d, 
J = 7 Hz, H3CC-4), 0.79 (3H, d, J = 6.5 Hz, H3CC-5'), 0.10 (3H, s, H3CSi), –0.02 (3H, s, H3CSi);  
13C NMR (CDCl3) : 214.5 (s, C-7), 213.6 (s, C-3), 139.0 (s, Ph), 128.8 (s, Ph), 128.4 (d ×2, Ph), 
126.0 (d ×2, Ph), 101.2 (d, C-2'), 88.7 (d, C-4'), 86.3 (d, C-6'), 73.7 (d, C-5), 70.7 (d, C-9), 51.6 (d, 
C-6), 49.7 (d, C-4), 48.6 (d, C-8), 37.3 (t, C-2), 34.5 (d, C-10), 33.1 (d, C-5'), 28.7 (d, C-1''), 26.0 (q 
×3, (CH3)3C), 20.6 (q, CH3C-1''), 18.2 (s, CSi), 15.9 (q, CH3C-8), 15.5 (q, CH3C-1''), 13.5 (q, CH3C-4), 
11.8 (q, CH3C-10), 11.3 (q, CH3C-5'), 9.9 (q, CH3C-6), 7.5 (q, C-1), –4.5 (q, CH3Si), –4.7 (q, CH3Si);  
HRMS m/z calcd. for C34H58O6Si+Na
+ 613.3894, found 613.3877 (ESI). 
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(2S,4S,6R,7R,8S)-7-((tert-Butyldimethylsilyl)oxy)-2-((2S,4S,5S,6S)-6-isopropyl-5-methyl-2-
phenyl-1,3-dioxan-4-yl)-4,6,8-trimethylundecane-3,5,9-trione (155). 
 
155 
 IBX (62 mg, 0.22 mmol) was added to a stirred solution of 155a (100 mg, 0.169 mmol) in 
DMSO (2 mL) at ambient temperature under argon. After 20 h, the mixture was diluted with 
water and extracted with ethyl acetate. The combined organic layers were washed sequentially 
with saturated NaHCO3, water and then brine, dried over Na2SO4, concentrated, and 
fractionated by FCC (10% ethyl acetate in hexane) to afford the title compound (98 mg, 98%). 
colorless oil, TLC Rf = 0.3 (10% ethyl acetate in hexane);  
*α]D –28 (c 0.80, CHCl3);  
IR max: 1716, 1691 cm
-1
;  
1H NMR (C6D6) : 7.58 (2H, ap d, J = 7.5 Hz, Ph), 7.23 (2H, ap dd, J = 7.5, 7.5 Hz, Ph), 7.15 (1H, t, J 
= 7.5 Hz, Ph), 5.29 (1H, s, HC-2'), 4.58 (1H, dd, J = 5.5, 6.5 Hz, HC-7), 4.22 (1H, q, J = 7 Hz, HC-4), 
3.29 (1H, dd, J = 3, 10 Hz, HC-4'), 3.12 (1H, dq, J = 6.5, 7 Hz, HC-6), 3.04 (1H, br d, J = 10 Hz, HC-
6'), 2.87 (1H, dq, J = 3, 7 Hz, HC-2), 2.61 (1H, dq, J = 5.5, 7 Hz, HC-8), 2.23 (1H, dq, J = 18, 7 Hz, 
HC-10), 2.08 (1H, dq, J = 18, 7 Hz, HC-10), 1.81-1.72 (2H, m, HC-1'', HC-5'), 1.39 (3H, d, J = 7 Hz, 
H3CC-4), 1.31 (3H, d, J = 7 Hz, H3C-1), 1.05 (3H, d, J = 7 Hz, H3CC-1''), 0.98 (3H, d, J = 7 Hz, H3CC-
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8), 0.96 (3H, t, J = 7 Hz, H3C-11), 0.92 (3H, d, J = 7 Hz, H3CC-1''), 0.90 (9H, s, (H3C)3C), 0.88 (3H, d, 
J = 7 Hz, H3CC-6), 0.62 (3H, d, J = 6.5 Hz, H3CC-5'), 0.12 (3H, s, H3CSi), 0.09 (3H, s, H3CSi);  
13C NMR (C6D6) : 210.6 (s, C-9), 208.7 (s, C-3), 208.4 (s, C-5), 139.6 (s, Ph), 128.8 (d, Ph), 128.4 
(d ×2, Ph), 126.4 (d ×2, Ph), 101.2 (d, C-2'), 85.8 (d, C-6'), 84.5 (d, C-4'), 74.7 (d, C-7), 57.9 (d, C-
4), 51.3 (d, C-8), 49.9 (d, C-2), 48.5 (d, C-6), 35.6 (t, C-10), 34.2 (d, C-5'), 28.6 (d, C-1''), 26.2 (q 
×3, (CH3)3C), 20.5 (q, CH3C-1''), 18.3 (s, CSi), 14.8 (q, CH3C-1''), 14.5 (q, CH3C-4), 13.9 (q, C-1), 
12.5 (q, CH3C-6), 11.7 (q, CH3C-5'), 11.6 (q, CH3C-8), 7.8 (q, C-11), –4.3 (q, CH3Si), –4.8 (q, CH3Si);  
HRMS m/z calcd. for C34H56O6Si+Na+ 611.3738, found 611.3720 (ESI). 
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(2S,4S,6R,7R,8S)-7-Hydroxy-2-((2S,4S,5S,6S)-6-isopropyl-5-methyl-2-phenyl-1,3-dioxan-4-yl)-
4,6,8-trimethylundecane-3,5,9-trione (156). 
 
156 
 From BOM. A suspension of Raney Nickel (W2; 0.5 mL settled volume) in EtOH (5 mL) 
was transferred to a solution of 160 (60 mg, 0.096 mmol) in EtOH (2 mL) and the resulting 
suspension was heated under reflux with vigorous stirring. After 3 h, the mixture was allowed 
to settle and then was decanted. The solid was suspended in ethyl acetate and the mixture was 
heated under reflux with vigorous stirring for 10 min, and then decanted. This washing 
procedure was repeated with acetone (×2) and methanol. The combined organic layers were 
filtered through Celite®, concentrated, and fractionated by FCC (30% ethyl acetate in hexane) to 
give the titled compound as a colorless oil (37 mg, 81%).  
 From TBS. Tris(dimethylamino)sulfonium difluorotrimethylsilicate (TAS-F; 51 mg, 0.19 
mmol) was added to a stirred solution of 155 (44 mg, 0.075 mmol) in DMF (1 mL) at ambient 
temperature under argon. After 2 h, the mixture was diluted with ethyl acetate and washed 
sequentially by saturated aq NaHCO3, water, and brine, dried over Na2SO4, concentrated and 
fractionated by FCC (30% ethyl acetate in hexane) to give the title compound as an ca. 1:1:0.04 
mixture of two keto and enol tautomeric forms, respectively (32 mg, 90%). 
colorless oil, TLC Rf = 0.3 (25% ethyl acetate in hexane);  
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*α+D +34 (c 1.2, CHCl3);  
IR max: 3457, 1715 cm
-1
;  
1H NMR (CDCl3) : 7.48-7.28 (5H, m, Ph), 5.44 (1H, ap s, HC-2'), 4.13 (0.5H, q, J = 7 Hz, HC-4), 
4.11 (0.5H, q, J = 7 Hz, HC-4), 3.63 (0.5H, dd, J = 4.5, 10 Hz, HC-4'), 3.60 (0.5H, dd, J = 4.5, 10 Hz, 
HC-4'), 3.58 (0.5H, d, J = 10 Hz, HO), 3.56 (0.5H, ddd, J = 5.5, 7, 9.5 Hz, HC-7), 3.38 (0.5H, d, J = 
9.5 Hz, HO), 3.37 (0.5H, ddd, J = 5, 7, 10 Hz, HC-7), 3.313 (0.5H, dd, J = 2, 10 Hz, HC-6'), 3.308 
(0.5H, dd, J = 2, 10 Hz, HC-6'), 3.05 (0.5H, dq, J = 4.5, 7 Hz, HC-2), 3.01 (0.5H, dq, J = 4.5, 7 Hz, 
HC-2), 2.83 (0.5H, dq, J = 7, 7 Hz, HC-8), 2.81 (0.5H, dq, J = 7, 7 Hz, HC-8), 2.62 (0.5H, dq, J = 5, 7 
Hz, HC-6), 2.61 (0.5H, dq, J = 5.5, 7 Hz, HC-6), 2.58-2.33 (2H, m, H2C-10), 2.07-1.97 (1H, m, HC-
1''), 1.90-1.76 (1H, m, HC-5'), 1.31 (1.5H, d, J = 7 Hz, H3C-1), 1.28 (1.5H, d, J = 7 Hz, H3C-1), 1.25 
(1.5H, d, J = 7 Hz, H3C-C4), 1.21 (1.5H, d, J = 7 Hz, H3C-C4), 1.10-0.98 (6H, m, H3CC-6, H3CC-8, 
H3CC-1'', H3CC-1''), 1.03 (1.5H, t, J = 7 Hz, H3C-11), 1.01 (1.5H, t, J = 7 Hz, H3C-11), 0.94 (3H, ap d, 
J = 7 Hz, H3C-C1''), 0.93 (1.5H, d, J = 7 Hz, H3C-C8), 0.89 (1.5H, d, J = 6.5 Hz, H3C-C5'), 0.84 (1.5H, 
d, J = 6.5 Hz, H3C-C5'), 0.83 (1.5H, d, J = 7 Hz, H3C-C6), 17.09 (0.08H, s, HO-enol), 1.93 (0.24H, s, 
H3CC-4 enol);  
13C NMR (CDCl3) : 216.4 and 216.0 (s, C-9), 213.1 and 212.2 (s, C-5), 210.4 and 208.6 (s, C-3), 
139.0 and 138.9 (s, Ph), 129.0 and 128.7 (d, Ph), 128.4 and 128.2 (d ×2, Ph), 126.3 and 126.1 
(Ph, Ph), 101.2 and 100.6 (d, C-2'), 86.0 and 85.9 (d, C-6'), 85.4 and 85.1 (d, C-4'), 77.6 and 77.4 
(d, C-5'), 60.8 and 58.1 (d, C-4), 50.1 and 50.0 (d, C-2), 48.5 and 48.0 (d, C-8), 47.7 and 46.4 (d, 
C-6), 36.8 and 36.3 (t, C-10), 35.4 and 35.3 (d, C-5'), 28.52 and 28.47 (d, C-1''), 20.51 and 20.47 
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(q, CH3-C1''), 15.1, 15.01, 14.98, 14.96, 14.94 and 14.91 (q, CH3-C4, CH3C-6, and CH3C-1''), 14.8 
and 14.7 (q, C-1), 13.3 and 12.9 (q, CH3-C4), 12.3 and 12.2 (q, CH3-C5'), 7.62 and 7.58 (q, C-11);  
HRMS m/z calcd. for C28H42O6+Na
+ 497.2874, found 497.2897 (ESI). 
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(4S,5R,6R,8S,10S,11S,12S,13S)-5-((tert-Butyldimethylsilyl)oxy)-11,13-dihydroxy-
4,6,8,10,12,14-hexamethylpentadecane-3,7,9-trione (157). 
 
157 
 Preparation of Palladium Black – Palladium acetate (200 mg, 0.891 mmol) in i-PrOH (5 
mL) was placed under hydrogen atmosphere (60 psi) and stirred until the brown solution 
became clear with a black precipitate (~15 minutes). The supernatant was removed by pipette 
and saturated aq NaHCO3 was added. After stirring for 15 min, the suspension was allowed to 
settle and the supernatant removed. The solid was washed (as above) with water (×3) and 
acetone (×2). Residual solvent was removed at high vacuum to yield neutral palladium black (93 
mg, 98%). 
 Freshly prepared palladium black (25 mg, 0.23 mmol) was added to a stirred solution of 
155 (28 mg, 0.048 mmol) in i-PrOH (10 mL) at ambient temperature under Ar. The reaction 
vessel was evacuated and placed under a H2 atmosphere (60 psi). After stirring for 16 h, the 
supernatant was removed and the Pd was washed with MeOH (×2). The organic layers were 
filtered through Celite® and the combined filtrate was concentrated and fractionated by FCC 
(20% ethyl acetate in hexane) to give the title compound (21 mg, 88%) that was predominantly 
a single hemiacetal form (HOC-13  O=C-9) in C6D6 solution.  
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colorless oil, TLC Rf = 0.3 (20% ethyl acetate in hexane);  
*α+D –16 (c 1.2, C6H6);  
IR max: 3418, 1699 cm
-1
;  
1H NMR (C6D6) : 4.97 (1H, s, HOC-9), 4.51 (1H, dd, J = 5, 7 Hz, HC-5), 3.65 (1H, dd, J = 2.5, 11 Hz, 
HC-13), 3.31 (1H, dq, J = 7, 7 Hz, HC-6), 3.08 (1H, ddd, J = 2.5, 2.5, 6.5 Hz, HC-11), 3.06 (1H, q, J = 
7 Hz, HC-8), 2.68 (1H, dq, J = 5, 7 Hz, HC-4), 2.35 (1H, dq, J = 7, 18 Hz, HC-2), 2.17 (1H, dq, J = 7, 
18 Hz, HC-2), 1.99 (1H, d, J = 6.5 Hz, HOC-11), 1.67 (1H, dqq, J = 2.5, 7, 7 Hz, HC-14), 1.53 (1H, 
dq, J = 2.5, 7 Hz, HC-10), 1.49 (3H, d, J = 7 Hz, H3CC-8), 1.24 (1H, ddq, J = 2.5, 10.5, 7 Hz, HC-12), 
1.19 (3H, d, J = 7 Hz, H3CC-10), 1.11 (3H, d, J = 7 Hz, H3C-15), 1.11 (3H, d, J = 7 Hz, H3CC-4), 1.10 
(3H, d, J = 7 Hz, H3CC-6), 1.02 (3H, t, J = 7 Hz, H3C-1), 0.93 (9H, s, (H3C)3C), 0.85 (3H, d, J = 7 Hz, 
H3C-15), 0.64 (3H, d, J = 7 Hz, H3CC-12), 0.16 (3H, s, H3CSi), 0.11 (3H, s, H3CSi);  
13C NMR (C6D6) : 215.8 (s, C-7), 211.0 (s, C-3), 101.2 (s, C-9), 77.1 (d, C-11), 76.5 (d, C-5), 72.5 
(d, C-13), 54.9 (d, C-8), 51.9 (d, C-4), 47.7 (d, C-6), 41.4 (d, C-10), 38.1 (d, C-12), 36.0 (t, C-2), 
28.8 (d, C-14), 26.6 (q ×3, (CH3)3)C), 21.1 (q, C-15), 18.7 (s, CSi), 15.2 (q, C-15), 14.5 (q, CH3C-10), 
14.3 (q, CH3C-6), 13.7 (q, CH3C-12), 12.3 (q, CH3C-4), 10.7 (q, CH3C-8), 8.2 (q, C-1), –3.8 (q, 
CH3Si), –4.5 (q, CH3Si);  
HRMS m/z calcd. for C27H52O6Si+Na
+ 523.3425, found 523.3429 (ESI). 
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(2R,3R,5S,6R,8S,9R,10S,11S)-10-Hydroxy-8-isopropyl-3,5,9,11-tetramethyl-2-((S)-3-
oxopentan-2-yl)-1,7-dioxaspiro[5.5]undecan-4-one (158). 
 
158 
 Et3N (1.2 mL, 0.87 g, 8.6 mmol) and Et3N•3HF (1.2 mL, 1.2 g, 7.4 mmol) were 
sequentially added to a stirred solution of 157 (15 mg, 0.030 mmol) in THF (1 mL) at ambient 
temperature under argon. After 3 days, the disappearance of starting material was evident by 
TLC analysis. The reaction mixture was diluted with ethyl acetate and washed sequentially with 
saturated NaHCO3, water and brine, dried over Na2SO4, concentrated, and fractionated by PTLC 
(30% ethyl acetate in hexane) to afford the title compound (9 mg, 82%) whose 1H and 13C NMR 
data closely matched those previously reported.10  
colorless oil, TLC Rf = 0.3 (30% ethyl acetate:in hexane);  
*α+D –60 (c 0.8, C6H6);  
IR max: 3501, 1724, 1713 cm
-1
;  
1H NMR (CDCl3) : 3.73 (1H, dd, J = 2, 11 Hz, HC-8), 3.61 (1H, dd, J = 2.5, 11.5 Hz, HC-2), 3.38 
(1H, ddd, J = 2.5, 3, 10.5 Hz, HC-10), 3.07 (1H, d, J = 10.5 Hz, HO), 2.65 (1H, dq, J = 7, 11.5 Hz, 
HC-3), 2.34 (1H, q, J = 6.5 Hz, HC-5), 2.26 (1H, dq, J = 2.5, 7 Hz, HC-2'), 2.07 (1H, dq, J = 7, 18.5 
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Hz, HC-4'), 1.98 (1H, dq, J = 7, 18.5 Hz, HC-4'), 1.71 (1H, dqq, J = 2. 7, 7 Hz, HC-1''), 1.40 (1H, dq, J 
= 3, 7 Hz, HC11), 1.27 (1H, ddq, J = 2.5, 7, 11 Hz, HC-9), 1.06 (3H, d, J = 6.5 Hz, H3CC-5), 0.98 (3H, 
d, J = 7 Hz, H3C-1'), 0.970 (3H, d, J = 7 Hz, H3CC-11), 0.966 (3H, d, J = 7 Hz, H3CC-1''), 0.96 (3H, d, 
J = 7 Hz, H3CC-9), 0.95 (3H, t, J = 7 Hz, H3C-5'), 0.94 (3H, d, J = 7 Hz, H3CC-3), 0.75 (3H, d, J = 7 Hz, 
H3CC-1'');  
13C NMR (C6D6) : 210.0 (s, C-3'), 207.9 (s, C-4), 104.9 (s, C-6), 79.6 (d, C-2), 74.9 (d, C-10), 73.2 
(d, C-8), 47.8 (d, C-2'), 46.3 (d, C-5), 45.3 (d, C-3), 39.6 (d, C-11), 38.3 (d, C-9), 36.5 (t, C-4'), 28.8 
(d, C-1''), 21.0 (q, CH3C-1''), 14.48 (q, C-1' or CH3C-1''), 14.44 (q, C-1' or CH3C-1''), 14.3 (q, CH3-
C3), 13.0 (q, CH3-C11), 12.2 (q, CH3-C9), 8.7 (q, CH3C-5), 8.0 (q, C-5');  
HRMS m/z calcd. for C21H36O5+Na
+ 647.2455, found 391.2454 (ESI). 
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(1S,2S,4R,5R,6S)-5-((Benzyloxy)methoxy)-1-hydroxy-1-((2S,4S,4aS,8R,8aR)-4-isopropyl-2-
phenylhexahydrothiopyrano[4,3-d][1,3]dioxin-8-yl)-2,4,6-trimethylnonane-3,7-dione (159). 
 
159 
 Anhydrous FeCl3 (12 mg, 76 mol) was added to a stirred solution of 153 (253 mg, 0.378 
mmol) in acetone (25 mL) at ambient temperature under argon. After 1 h, the mixture was 
diluted with ethyl acetate and washed sequentially with water and brine, dried over Na2SO4, 
concentrated, and fractionated by FCC (25% ethyl acetate in hexane) to give the title compound 
(217 mg, 92%). 
colorless oil, TLC Rf = 0.3 (30% Et2O in toluene);  
*α+D +16 (c 1.0, CHCl3);  
IR max: 3498, 1708 cm
-1
;  
1H NMR (CDCl3) : 7.50-7.25 (10H, m, Ph ×2), 5.55 (1H, s, HC-2'), 4.63 (2H, s, H2CO2), 4.49 (1H, d, 
J = 11.5 Hz, H2CPh), 4.44 (1H, d, J = 11.5 Hz, H2CPh), 4.31 (1H, ddd, J = 4, 4, 4 Hz, HC-1), 4.16 (1H, 
dd, J = 4.5, 8.5 Hz, HC-5), 3.52 (1H, dd, J = 9.5, 10 Hz, HC-8a'), 3.38 (1H, dd, J = 2, 10 Hz, HC-4'), 
3.03 (1H, dq, J = 4, 7 Hz, HC-2), 3.01 (1H, dq, J = 8.5, 7 Hz, HC-4), 2.90 (1H, dq, J = 4.5, 7 Hz, HC-
6), 2.82 (1H, ddd, J = 2.5, 3, 14 Hz, HC-7'), 2.69 (1H, dd, J = 11.5, 14 Hz, HC-7'), 2.63 (1H, d, J = 4 
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Hz, HO), 2.55-2.39 (3H, m, H2C-8, HC-5'), 2.31 (1H, dd, J = 12, 13 Hz, HC-5'), 2.13 (1H, dddd, J = 
3.5, 4, 10, 11.5 Hz, HC-8'), 2.05 (1H, dddd, J = 3.5, 9.5, 10, 12 Hz, HC-4a'), 1.94 (1H, dqq, J = 2, 7, 
7 Hz, HC-1''), 1.15 (3H, d, J = 7 Hz, H3CC-2), 1.05 (3H, d, J = 7 Hz, H3CC-1''), 1.03 (3H, d, J = 7 Hz, 
H3CC-6), 1.01 (3H, t, J = 7.5 Hz, H3C-9), 0.95 (3H, d, J = 7 Hz, H3CC-1''), 0.82 (3H, d, J = 7 Hz, H3CC-
4);  
13C NMR (CDCl3) : 217.1 (s, C-3), 212.2 (s, C-7), 139.0 (s, Ph), 137.7 (s, Ph), 128.9 (d, Ph), 128.7 
(d ×2, Ph), 128.3 (d ×2, Ph), 128.01 (d, Ph), 127.96 (d ×2, Ph), 126.3 (d ×2, Ph), 101.2 (d, C-2'), 
95.9 (t, OCH2O), 84.0 (d, C-4'), 82.4 (d, C-8a'), 81.7 (d, C-5), 70.6 (t, CH2Ph), 69.5 (d, C-1), 50.9 (d, 
C-2), 49.1 (d, C-6), 47.4 (d, C-4), 46.2 (d, C-8'), 44.0 (d, C-4a'), 35.3 (t, C-8), 28.4 (d, C-1''), 28.2 (t, 
C-7'), 27.6 (t, C-5'), 20.2 (q, CH3C-1''), 15.0 (q, CH3C-1''), 13.4 (q, CH3C-4), 11.1 (q, CH3C-6), 10.9 
(q, CH3C-2), 8.0 (q, C-9);  
HRMS m/z calcd. for C36H50O7S 626.3277, found 626.3261 (FD). 
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(4R,5R,6S)-5-((Benzyloxy)methoxy)-1-hydroxy-1-((2S,4S,4aS,8S,8aS)-4-isopropyl-2-
phenylhexahydrothiopyrano[4,3-d][1,3]dioxin-8-yl)-2,4,6-trimethylnonane-1,3,7-trione (160). 
 
160 
 IBX (140 mg, 0.500 mmol) was added to a stirred solution of 159 (205 mg, 0.327 mmol) 
in DMSO (5 mL) at ambient temperature under argon. After 20 h, the mixture was diluted with 
water and extracted with ethyl acetate. The combined organic layers were washed sequentially 
with saturated NaHCO3, water and then brine, dried over Na2SO4, concentrated, and 
fractionated by FCC (10% ethyl acetate in hexane) to afford the title compound (187 mg, 92%) 
as an ca. 5:9:1 mixture of enol and two keto forms, respectively. 
colorless oil, TLC Rf = 0.3 (20% ethyl acetate:in hexane);  
*α+D +19 (c 1.0, CHCl3);  
IR max: 1713 cm
-1
;  
1H NMR (CDCl3) : 17.15 (0.5H, s, HO enol), 7.42-7.21 (15H, m, Ph ×2), 5.51 (0.5H, s, HC-2' enol), 
5.49 (1H, s, HC-2' keto), 4.66 (1H, d, J = 7 Hz, OCH2O keto), 4.64 (1H, d, J = 7 Hz, OCH2O keto), 
4.59 (0.5H, d, J = 7 Hz, OCH2O enol), 4.53 (0.5H, d, J = 7 Hz, OCH2O enol), 4.51 (1H, d, J = 12 Hz, 
H2CPh keto), 4.46 (1H, d, J = 12 Hz, H2CPh keto), 4.37 (0.5H, d, J = 12 Hz, H2CPh enol), 4.31 
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(0.5H, d, J = 12 Hz, H2CPh enol), 4.17 (1.5H, ap dd, J = 5, 7 Hz, HC-5 keto & enol), 3.98 (1H, q, J = 
7 Hz, CH3C-2 keto), 3.89 (0.5H, dd, J = 10, 10 Hz, HC-8a' enol), 3.72 (1H, dd, J = 10, 10 Hz, HC-8a' 
keto), 3.45 (0.5H, dd, J = 2, 10 Hz, HC-4' enol), 3.41 (1H, dd, J = 2, 10 Hz, HC-4' keto), 3.34 (0.5H, 
ddd, J = 3, 10, 11.5 Hz, HC-8' enol), 3.21 (1H, dq, J = 7, 7 Hz, HC-4 enol), 3.08 (1H, ddd, J = 3, 10, 
11.5 Hz, HC-8' keto), 3.05 (0.5H, dd, J = 11.5, 13.5 Hz, HC-7' enol), 3.01-2.87 (3.5H, m, HC-4 keto, 
HC-6 keto & enol, HC-7' keto ), 2.72 (1H, ddd, J = 2, 3, 13.5 Hz, HC-7' keto), 2.61-2.30 (7.5H, m, 
H2C-8 keto & enol,H2C-5' keto & enol, HC-7' enol), 2.12 (0.5H, dddd, J = 3, 10, 10, 11.5 Hz, HC-
4a' enol), 2.05 (1H, dddd, J = 3.5, 10, 10, 11.5 Hz, HC-4a' keto), 1.96 (1.5H, s, H3CC-2 enol), 2.00-
1.88 (1.5H, m, HC-1'' keto & enol), 1.25 (3H, d, J = 7 Hz, H3CC-2 keto), 1.11-1.06 (9H, m, H3CC-6 
keto & enol, H3CC-1'' keto & enol, ), 1.04 (1.5H, d, J = 7 Hz, H3CC-4 enol), 1.04 (1.5H, t, J = 7 Hz, 
H3C-9 enol), 1.02 (3H, t, J = 7 Hz, H3C-9 keto), 1.00-0.96 (7.5, m, H3C-4 keto, H3CC-1'' keto & 
enol);  
13C NMR (CDCl3)  (major keto form): 212.6 (s, C-7), 210.5 (s, C-3), 209.2 (s, C-1), 138.4 (s, Ph), 
137.6 (s, Ph), 128.8 (s, Ph), 128.65 (d ×2, Ph), 128.27 (d ×2, Ph), 128.02 (d ×2, Ph), 127.98 (s, Ph), 
125.88 (d ×2, Ph), 100.6 (d, C-2'), 95.67 (t, OCH2O), 83.76 (d, C-4), 82.9 (d, C-8a'), 81.3 (d, C-5), 
70.5 (t, CH2Ph), 62.0 (d, C-2), 55.3 (d, C-8'), 48.9 (d, C-6), 47.9 (d, C-4), 43.3 (d, C-4a'), 35.6 (d, C-
8), 29.9 (t, C-7'), 28.37 (d, C-1''), 27.53 (t, C-5'), 20.09 (q, CH3C-1''), 15.04 (q, CH3C-1''), 13.23 (q, 
CH3C-4), 11.8 (q, CH3C-2), 11.5 (q, CH3C-6), 7.92 (q, C-9); (enol form): 212.8 (s, C-7), 195.4 (s, C-
3), 193.0 (s, C1), 138.7 (s, Ph), 137.9 (s, Ph), 128.61 (s, Ph), 128.57 (d ×2, Ph), 128.08 (d ×2, Ph), 
127.85 (d ×2, Ph), 127.83 (s, Ph), 125.94 (d ×2, Ph), 106.4 (s, C-2), 100.4 (d, C-2'), 95.69 (t, 
OCH2O), 83.71 (d, C-4), 81.6 (d, C-5), 81.4 (d, C-8a'), 70.3 (t, CH2Ph), 48.99 (d, C-6), 48.2 (d, C-8'), 
 130 
 
43.5 (d, C-4a'), 41.4 (d, C-4), 35.4 (d, C-8), 30.4 (t, C-7'), 28.41 (d, C-1''), 27.62 (t, C-5'), 20.1 (q, 
CH3-C1''), 15.02 (q, CH3-C1''), 13.29 (q, CH3-C4), 12.4 (q, CH3-C2), 12.0 (q, CH3-C-6), 8.0 (q, C-9);  
HRMS m/z calcd. for C36H48O7S+Na
+ 647.3013, found 647.3021 (ESI). 
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4-epi-Dolabriferol (170).  
 
170 
 A solution of DBU (5 mg; 0.03 mmol) in C6D6 (0.1 mL) was added to a solution of 4 (12 
mg, 0.031 mmol) in C6D6 (0.6 mL) in a 5 mm NMR tube band the reaction was monitored by 
1H 
NMR. After 5 days, the mixture was diluted with ethyl acetate and washed sequentially with 
saturated aq citric acid, saturated aq NaHCO3 and brine, dried over Na2SO4, concentrated, and 
fractionated by PTLC (50% ethyl acetate in hexane) to give a 6:3:1 mixture of 4-epi-dolabriferol 
170, dolabriferol 1, and an unknown dolabriferol epimer, respectively (4.5 mg, 38%), an 
inseparable 2:1 mixture of 173 and 174 (4 mg, 30%), and a mixture of hemiacetals (4 mg, 30%). 
The fraction containing 170 dolabriferol 1, and an unknown epimer was further fractionated by 
PTLC (30% ethyl acetate in hexane) to give a 3:1 mixture of dolabriferol 1 and an unknown 
dolabriferol epimer, respectively (1.5 mg, 13%), and the title compound (3 mg, 25%). 
colorless oil, TLC Rf = 0.3 (40% Et2O in hexane);  
*α+D –8 (c 0.3, C6H6);  
IR max: 3445, 1732, 1712 cm
-1
;  
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1H NMR (CDCl3) : 5.25 (1H, dd, J = 3, 3 Hz, HC-15), 4.24 (1H, ddd, J = 3, 4.5, 9 Hz, HC-6), 4.03 
(1H, d, J = 4.5 Hz, HOC-6), 3.63 (1H, dd, J = 2, 10.5 Hz, HC-18), 2.74 (1H, dq, J = 7, 9 Hz, HC-4), 
2.63 (1H, dq, J = 3, 7.5 Hz, HC-7), 2.61 (1H, br s, HOC-12), 2.56 (2H, ap q, J = 7 Hz, H2C-2), 1.87 
(1H, dq, J = 3, 7 Hz, HC-13), 1.83 (1H, dqq, J = 2, 7, 7 Hz, HC-19), 1.76 (1H, ddq, J = 3, 7, 10.5 Hz, 
HC-16), 1.68-1.57 (2H, m, H2C-10), 1.27 (3H, d, J = 7.5 Hz, H3C-8), 1.06 (3H, t, J = 7 Hz, H3C-1), 
1.005 (3H, d, J = 7 Hz, H3C-5 or H3C-20), 0.998 (3H, d, J = 7 Hz, H3C-5 or H3C-20), 0.92 (3H, d, J = 7 
Hz, H3C-14), 0.90 (3H, t, J = 7.5 Hz, H3C-11), 0.83 (3H, d, J = 7 Hz, H3C-21), 0.79 (3H, d, J = 7 Hz, 
H3C-17);  
13C NMR (CDCl3) : 215.5 (s, C-3), 174.9 (s, C-9), 98.9 (s, C-12), 76.4 (d, C-15), 72.6 (d, C-6 or C-
18), 72.5 (d, C-6 or C-18), 47.9 (d, C-4), 42.3 (d, C-7), 39.6 (d, C-13), 37.1 (t, C-2), 36.3 (d, C-16), 
32.9 (t, C-10), 28.1 (d, C-19), 20.5 (q, C-20), 14.1 (q, C-21), 13.9 (q, C-5), 13.1 (q, C-17), 12.7 (q, 
C-14), 10.3 (q, C-8), 7.7 (q, C-1), 7.4 (q, C-11);  
HRMS m/z calcd. for C21H38O6+Na 409.2561, found 409.2579 (ESI). 
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(3S,4S,5R,6S)-4-Hydroxy-6-isopropyl-3,5-dimethyltetrahydro-2H-pyran-2-one (173) and 
(2R,3S,4S,5R,6S)-3-Ethyl-3,5-dihydroxy-2,4,6-trimethylcyclohexanone (174).  
 
173                           174 
 A 2:1 mixture of 173 and 174, respectively was obtained is preparation of 170. Lactone 
173 is a known compound34 and the 1H and 13C NMR data for the major component of the 
mixture closely matched those reported for 173. The minor component is tentatively assigned 
as 174 based on its 1H and 13C NMR data. 
Lactone 173 
1H NMR (CDCl3) : 4.32 (1H, dd, J = 2, 11 Hz, HC-6), 3.87 (1H, br s, HC-4), 2.54 (1H, dq, J = 3, 7 
Hz, HC-3), 1.98 (1H, ddq, J = 2, 11, 7 Hz, HC-5), 1.90 (1H, dqq, J = 2, 7, 7 Hz, HC-1'), 1.84 (1H, br s, 
HO), 1.36 (3H, d, J = 7 Hz, H3CC-3), 1.14 (3H, d, J = 7 Hz, H3CC-1'), 1.09 (3H, d, J = 7 Hz, H3CC-5), 
0.92 (3H, d, J = 7 Hz, H3CC-1');  
13C NMR (CDCl3) : 174.0 (s, C-1), 85.1 (d, C-6), 73.6 (d, C-4), 42.6 (d, C-3), 36.2 (d, C-5), 29.2 (q, 
C-1'), 20.3 (q, H3CC-1'), 14.5 (q, H3CC-5), 14.3 (q, H3CC-1'), 13.0 (q, H3CC-3) 
Cyclohexanone 174 
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1H NMR (CDCl3) : 4.11 (1H, br s, HC-5), 2.73 (1H, ddq, J = 1, 3.5, 6.5 Hz, HC-6), 2.67 (1H, dq, J = 
1, 6.5 Hz, HC-2), 2.42 (1H, bs, HO), 2.21 (1H, dq, J = 3, 7 Hz, HC-4), 1.69 (1H, dq, J = 14.5, 7.5 Hz, 
HC-1'), 1.51 (1H, dq, J = 14.5, 7.5 Hz, HC-1'), 1.25 (3H, d, J = 7 Hz, H3CC-4), 1.18 (3H, d, J = 6.5 Hz, 
H3CC-6), 1.08 (3H, d, J = 6.5 Hz, H3CC-2), 0.90 (3H, t, J = 7.5 Hz, H3C-2');  
13C NMR (CDCl3) : 211.5 (s, C-1), 83.6 (d, C-3), 81.5 (d, C-5), 51.2 (d, C-6), 50.7 (d, C-2), 39.2 (d, 
C-4), 29.8 (t, C-1'), 12.0 (q, H3CC-4), 11.0 (q, H3CC-6), 8.9 (q, H3CC-2'), 7.1 (q, H3CC-2) 
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